Check for updates

OPEN ACCESS

EDITED BY Shazia Qasim Jamshed, Sultan Zainal Abidin University, Malaysia

REVIEWED BY Sadia Shakeel, DOW University of Health Sciences (DUHS), Pakistan Yongsheng Chen, Jinan University, China Márió Gajdács, University of Szeged, Hungary Imma Pagano, University of Salerno, Italy

*CORRESPONDENCE Songwei Li, lswhnszyy@hactcm.edu.cn

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 30 April 2022 ACCEPTED 22 November 2022 PUBLISHED 07 December 2022

CITATION

Gong X, Li H, Guo H, Wu S, Lu C, Chen Y and Li S (2022), Efficacy and safety of total glucosides of paeony in the treatment of systemic lupus erythematosus: A systematic review and meta-analysis. *Front. Pharmacol.* 13:932874. doi: 10.3389/fphar.2022.932874

COPYRIGHT

© 2022 Gong, Li, Guo, Wu, Lu, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Efficacy and safety of total glucosides of paeony in the treatment of systemic lupus erythematosus: A systematic review and meta-analysis

Xiaohong Gong^{1,2†}, Huan Li^{1,2†}, Hongtao Guo², Shangwen Wu^{1,2}, Chaoqun Lu¹, Yiming Chen¹ and Songwei Li^{1,2,3}*

¹Henan University of Chinese Medicine, Zhengzhou, China, ²The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China, ³Henan Provincial Hospital of Traditional Chinese Medicine, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

Background: Total glucosides of paeony (TGP), extracted from the Chinese medicine *Paeonia lactiflora* Pall., have been proven to be effective in various autoimmune diseases. We aim to systematically evaluate the efficacy and safety of TGP combined with different conventional therapeutic agents in the treatment of systemic lupus erythematosus (SLE).

Methods: Eight databases were searched for randomized controlled studies of TGP for SLE. The search time was set from the establishment of the databases to March 2022. The risk of bias was assessed by the Cochrane Evaluation Manual (5.1.0), RevMan 5.3 software was used for meta-analysis, and the certainty of the evidence was assessed by the GRADE methodology.

Results: A total of 23 articles were included, including 792 patients overall in the treatment group and 781 patients overall in the control group. The meta-analysis results showed that TGP combined with conventional treatments was superior to the conventional treatments in reducing the SLE disease activity and the incidence of adverse reactions (SMD_{TGP+GC+CTX} = -1.98, 95% Cl = [-2.50, -1.46], p < 0.001; SMD_{TGP+GC+HCQ} = -0.65, 95% Cl = [-1.04, -0.26], p < 0.001; SMD_{TGP+GC+TAC} = -0.94, 95% Cl = [-1.53, -0.34], p < 0.05; SMD_{TGP+GC} = -1.00, 95% Cl = [-1.64, -0.36], p < 0.05; and RR_{TGP+GC+CTX} = 0.37, 95% Cl = [0.21, 0.64], p < 0.001). The results also showed that TGP helped improve other outcomes related to SLE disease activity, such as complement proteins (C3 and C4), immunoglobulins (IgA, IgM and, IgG), ESR, CRP, 24 h urine protein, and recurrence rate. In addition, TGP may also be effective in reducing the average daily dosage of glucocorticoids (GCs) and the cumulative dosage of cyclophosphamide (CTX). The certainty of the evidence was assessed as moderate to low.

Conclusion: TGP is more effective and safer when used in combination with different conventional therapeutic agents. It helped reduce the disease activity of SLE and the incidence of adverse reactions. However, we should be cautious about these conclusions as the quality of the evidence is poor. Future studies should focus on improving the methodology. High-quality randomized

controlled trials (RCTs) will be necessary to provide strong evidence for the efficacy of TGP for SLE.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42021272481

KEYWORDS

total glucosides of paeony, meta-analysis, safety, efficacy, systemic lupus erythematosus (SLE)

1 Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement, recurrent relapses and remissions, and the presence of a large number of autoantibodies in the body as the main clinical features, which can cause irreversible damage to the involved organs and eventually lead to the death of the patients if left untreated (Durcan et al., 2019; Fava and Petri, 2019). It is reported the global prevalence of SLE is about 0-241/100,000, and the prevalence of SLE in China is about 30-100/100,000, ranking second in the world (Li et al., 2013; Rees et al., 2017; Chinese Rheumatology Association, 2020). With the development of gene and molecular biology technology, the research on the pathogenesis diagnosis and treatment of SLE has made rapid progress. Although the 10-year survival rate for patients with SLE improved significantly from 63.2% in the 1950s to 91.4% in 2000s (Mu et al., 2018), the allcause and cause-specific mortality rates remain significantly higher than the general population (Jorge et al., 2018; Bultink et al., 2021).

Drugs used in the treatment of SLE include glucocorticoids (GCs), hydroxychloroquine (HCQ), immunosuppressive (IS) drugs, and biological agents such as belimumab and rituximab (RTX). (Fanouriakis et al., 2019). However, long-term HCQ therapy can lead to retinal toxicity, with the incidence of retinal abnormalities exceeding 10% after 20 years of consecutive use (Knight et al., 2016; Kao et al., 2022). A longterm GC treatment can cause irreversible organ damage (Chen et al., 2018; Kwon et al., 2018). Combining IS drugs facilitates more rapid GC reduction and may prevent disease recurrence. However, the teratogenic potential of methotrexate (MTX) and azathioprine (AZA) and the toxic effect of cyclophosphamide (CTX) on the gonads have limited their widespread application in women and men of reproductive age (Knight et al., 2016; Martins et al., 2017; Tamirou et al., 2017). RTX and belimumab are usually considered following the failure of first-line therapies or relapsing disease (Iaccarino et al., 2015; Olfat et al., 2015; Fanouriakis et al., 2019; Huang et al., 2022). However, the price and potential risk of infection pose a huge financial burden and concern for patients (Steiger et al., 2022). Therefore, a safer and more effective therapeutic strategy needs to be explored.

Total glucosides of paeony (TGP) are a group of active glycosides extracted from the roots of *Paeonia lactiflora* Pall. (Bai shao in Chinese), which mainly include paeoniflorin, paeonin, albiflorin, and benzoylpaeoniflorin (Figure 1).

Paeoniflorin is the major active component of TGP. It constitutes more than 40% of TGP (Yang et al., 2021). Research studies have shown that TGP has analgesic, antiinflammatory, immunomodulatory, and antioxidant functions (He and Dai, 2011; Zhang and Wei, 2020). TGP is often used as an adjunctive therapy for autoimmune diseases. It has been successfully utilized in the clinical treatment of autoimmune diseases such as rheumatoid arthritis (Luo et al., 2017; Huang et al., 2019a), primary Sjogren's syndrome (Feng et al., 2019), and ankylosing spondylitis (Huang et al., 2019b). The combination of TGP with conventional therapeutic agents can reduce adverse reactions and have synergistic effects in the treatment of autoimmune diseases (Jiang et al., 2020). In recent years, TGP has also been increasingly used to treat SLE. Previous clinical and experimental studies have shown that TGP can alleviate typical symptoms, increase the expression rate of CD4+CD25+T cells, regulate the TLR9/MyD88/NF-KB signaling pathway, reduce the levels of CD40+, sVCAM-1, IL-18, VEGF, and MMP-3, and inhibit the expression of inflammatory factors, playing an immunomodulatory and anti-SLE renal damage role. This indicates that TGP may be a potential new therapeutic agent for the modern treatment of SLE (Wu et al., 2020; Wang et al., 2021; Wu et al., 2022).

To date, only one systematic review has evaluated the efficacy of TGP in different courses of treatment for SLE (Chen et al., 2022). However, no study followed the statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to evaluate the efficacy and safety of TGP in combination with different conventional therapeutic agents for the treatment of SLE. This study aims to investigate the efficacy and safety of TGP combined with different conventional therapeutic agents for the treatment of SLE, thus providing an evidence-based basis for future clinical treatment of SLE.

2 Methods

2.1 Protocol registration

This meta-analysis followed the PRISMA statement (Page et al., 2021). The study protocol was registered at PROSPERO: https://www.crd.york.ac.uk/PROSPERO (Registration number: CRD42021272481).



2.2 Search strategy

The method of combining subject words and free words was used to search the randomized controlled trials (RCTs) of TGP for SLE in eight databases including China National Knowledge Infrastructure (CNKI), the Chinese Science Technology Journal Database (VIP), WanFang Database, SinoMed, PubMed, Web of Science, Cochrane Library, and Embase from the inception to March 2022. The detailed search strategies for the eight databases are shown in Supplementary Table S1.

2.3 Inclusion criteria

2.3.1 Study types

We included RCTs.

2.3.2 Participant types

The patients were included in accordance with any of the SLE classification criteria (Hochberg, 1997; Petri et al., 2012; Aringer et al., 2019) and were in the active disease stages. There were no restrictions on age and gender.

2.3.3 Intervention types

The control groups were treated according to the European League Against Rheumatism (EULAR) guidelines for SLE (Fanouriakis et al., 2019) or the Chinese treatment guidelines (Chinese Rheumatology Association, 2020) including GC, CTX, HCQ, and TAC, while the experimental groups were treated with TGP combined with the control group drugs.

2.3.4 Outcome types

Primary outcome variables include SLE Disease Activity Index (SLEDAI) and the incidence of adverse reactions.

Secondary outcome variables include complements (C3 and C4), immunoglobulins (IgA, IgG, and IgM), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 24 h urine protein, average daily dosage of GC, cumulative dosage of CTX, and recurrence rate.

The efficacy outcomes include: SLEDAI, C3, C4, IgA, IgG, IgM, ESR, CRP, 24 h urine protein, average daily dosage of GC,

cumulative dosage of CTX, and recurrence rate. The safety outcomes include the incidence of adverse reactions.

2.4 Exclusion criteria

The exclusion criteria include: 1) patients combined with rheumatic immune diseases other than SLE, 2) experimental or control group taking other herbal medicines, 3) literature with duplicate publications, animal experiments, case reports, reviews of progress, and data errors, and 4) inability to obtain the full text.

2.5 Study selection

Two researchers (GXH and LCQ) independently searched the eight databases, imported the articles into EndNote X9, and selected articles according to the inclusion and exclusion criteria after deduplication. Any disagreements between the two researchers were resolved by discussion with a third researcher (LH).

2.6 Data extraction

Two authors (WSW and CYM) independently extracted the relevant data according to the predefined criteria. The data included: study designs, year of publication, participant characteristics, diagnostic criteria, methodology, intervention and control approaches, treatment duration, outcome measures, and adverse reactions. Any disagreements between the two researchers were resolved by discussion with a third researcher (LSW).

2.7 Risk of bias assessment

Two researchers (GXH and WSW) independently assessed the risk of bias of the included 23 studies by referring to the Cochrane Evaluation Manual (5.1.0) (Sterne et al., 2019), mainly from the following seven aspects: 1) random sequence generation, 2) allocation concealment, 3) blinding of outcome assessment, 4) blinding of outcome evaluation, 5) incomplete outcome data, 6) selective reporting, and 7) other biases. Any disagreements between the two researchers were resolved by discussion with the third researcher (LSW).

2.8 Data analysis and bias assessment

RevMan 5.3 software was applied to perform data analysis on the continuous and dichotomous data extracted from 23 studies. The relative risk (RR) was used to represent the binary variables, such as the incidence of adverse reactions and the recurrence rate. The standardized mean difference (SMD) was used to represent the continuous variables, such as SLEDAI, C3, C4, IgA, IgG, IgM, ESR, CRP, 24 h urine protein, average daily dosage of GC, and accumulation dosage of CTX. Subgroup analyses were performed according to conventional therapeutic agents. All data were described with the effect size and 95% confidence intervals (CI). When there was significant heterogeneity ($I^2 \ge 50\%$, $p \le 0.05$), a random-effects model was used; otherwise, a fixed-effects model was used. If the heterogeneity is large, sensitivity analyses were carried out by removing the articles one by one and analyzing the causes of heterogeneity by rereading the full text. A funnel plot of adverse reaction rates was plotted to assess publication bias.

2.9 Certainty assessment

Two researchers (LSW and GHT) independently assessed the grade of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, which can be downgraded from five factors (study limitation, consistency of effect, imprecision, indirectness, and publication bias) or upgraded from three reasons (large magnitude of effect, reasonable residual confounding effects, and dose-response gradient). The certainty of evidence was rated as "very low," "low," "moderate," or "high" (Guyatt et al., 2008; Balshem et al., 2011).

3 Results

3.1 Study selection

A total of 389 articles including 204 duplications were initially retrieved after eight databases were searched by subject words combined with free words. A total of 23 articles were finally included according to the inclusion and exclusion criteria through reading abstracts and full texts. The flow diagram for selection of studies is shown in Figure 2.

3.2 Study characteristics

There were 23 RCTs of TGP combined with conventional therapeutic agents for SLE included in this study, including 1,573 patients, with 792 patients overall in the experimental group and 781 patients overall in the control group. All studies were published in Chinese from 2009 to 2020. The sample size ranged from 40 to 106 cases. The control group was treated with conventional therapeutic agents including CTX, TAC, GC, and HCQ, while the experimental group was treated with TGP combined with the drugs of the control groups. The disease



course varied from 1 year to 10 years. The duration of treatment ranged from 1 month to 1 year In total 18 studies reported the primary outcomes of SLEDAI and the incidence of adverse reactions. Other studies reported the second outcome. The baseline data were consistent between the two groups. The basic characteristics of the included studies are shown in Table 1.

3.3 Risk of bias assessment

The risk of bias of 23 studies was evaluated according to the Cochrane Evaluation Manual (5.1.0). Seven studies (Lin and Liu, 2016; Cai et al., 2017; Li Z. et al., 2018; Yang and Li, 2019; Wu et al., 2020; Xu, 2020; Zhao et al., 2020) used the random number table method to generate random sequences. Two studies (Peng, 2018; Yu et al., 2019) used the order of admission. One study

(Xue and Lyu, 2019) used the coin toss method. One study (Xiang, 2020) used the touch-ball method. The rest of the studies only mentioned randomness and did not elaborate on the method of random sequence generation. None of the studies stated whether a blinding was used, whether allocation concealment was used, or whether the outcome assessment was blinded. All studies were fully reported according to prespecified outcome measures. The risk of bias for the included studies is shown in Figure 3.

3.4 Efficacy outcomes

3.4.1 SLEDAI

A total of 18 studies reported SLEDAI as the primary outcome, including 598 patients overall in the experimental

TABLE 1 Basic characteristics of included studies.

Study ID Gender (male/		Sample size (T/C)	Age (yea	rs)	Course o	of disease	Intervent	ion	Treatment duration	Outcome
	female)	()	Т	С	Т	С	Т	С		
Zhao et al. (2020)	8/98	106 (53/53)	38.14 ± 3.24	34.13 ± 3.22	9.91 ± 2.29y	9.82 ± 2.33y	TGP 0.6 g tid + CTs	GC + HCQ	3 m	023®
Zhang et al. (2020)	31/33	64 (32/32)	38.2 ± 0.5	37.9 ± 1.2	12.4 ± 0.4 m	11.8 ± 0.7 m	TGP 0.6 g bid + CTs	GC + TAC	6 m	1
Yu et al. (2019)	11/49	60 (30/30)	37.84 ± 5.9 3	37.94 ± 5.82	5.92 ± 1.84y	5.87 ± 1.90y	TGP 0.6 g bid + CTs	GC + CTX	6 m	02780113
Yang and Li, (2019)	8/98	106 (53/53)	41.5 ± 4.1	42.7 ± 5.2	3.4 ± 1.1y	3.7 ± 1.3y	TGP 0.6 g tid + CTs	GC	3 m	1237®
Xue and Lyu (2019)	6/54	60 (30/30)	38.15 ± 3.20	38.12 ± 3.25	1.81 ± 0.32y	1.82 ± 0.35y	TGP 0.6 g bid/tid + CTs	GC + HCQ	6 m	0371
Xu, (2020)	21/51	72 (36/36)	36.82 ± 6.2	9	5.39 ± 1.67y	5.25 ± 1.72y	TGP 0.6 g bid/tid + CTs	GC + CTX	12 m	090000
Xu, (2015)	19/34	53 (27/26)	42.7 ± 5.30		5.9 ± 1.7y	5.3 ± 1.1y	TGP 0.6 g bid/tid + CTs	GC + CTX	1 m	09003
Wu et al. (2020)	19/55	54 (27/27)	36.82 ± 6.3	1	3.24 ± 1.20y	3.19 ± 1.02y	TGP 0.6 g bid/tid + CTs	GC + CTX	3 m	23456@8
Wang and Wang, (2015)	6/36	42 (21/21)	27.34 ± 7.65	29.28 ± 8.95	NR		TGP 0.6 g tid + CTs	GC	3 m	00
Liu, (2016)	12/74	86 (43/43)	44.2 ± 9.4	44.2 ± 9.4	6.9 ± 3.4y		TGP 0.6 g tid + CTs	GC	NR	451213
Li et al. (2018a)	16/74	90 (45/45)	32.15 ± 5.37	33.21 ± 4.94	32.81 ± 9.53 m	32.07 ± 9.86 m	TGP 0.6 g bid + CTs	GC + TAC	6 m	1234560003
Chen, (2013)	4/37	41 (21/20)	27.5 ± 6.7		NR		TGP 0.6 g tid + CTs	GC + CTX	1.5 m	09003
Li et al. (2013)	6/88	94 (47/47)	43.1	42.8	7.9y	7.4y	TGP 0.6 g tid + CTs	GC	NR	450
Li and Zheng, (2020)	14/52	66 (33/33)	47.21 ± 7.4	2	NR		TGP 0.6 g bid + CTs	GC + CTX	1 m	190123
Lin and Liu, (2016)	17/34	51 (26/25)	17-34		NR		TGP 0.6 g tid + CTs	GC + CTX	NR	090028
Cai et al. (2017)	9/51	60 (30/30)	33.2 ± 5.1		2.47 ± 0.78y	2.56 ± 0.82y	TGP 0.6 g tid + CTs	GC + CTX	6 m	12790113
Peng, (2018)	10/30	40 (20/20)	43.3 ± 4.9		5.5 ± 1.2y	5.7 ± 1.1y	TGP 0.6 g tid + CTs	GC + CTX	3 m	1901@3
Xiang, (2020)	17/53	70 (35/35)	39.2 ± 4.3		6.8 ± 1.7y	6.7 ± 1.6y	TGP 0.6 g bid/tid + CTs	GC + CTX	6 m	0900
Feng et al. (2017)	19/34	53 (27/26)	42.7 ± 5.30		5.9 ± 1.7y	5.3 ± 1.1y	TGP 0.6 g tid + CTs	GC + CTX	NR	029000
Sun, (2013)	44/52	96 (48/48)	34.6 ± 4.10		2.4 ± 0.8y	2.5 ± 0.7y	TGP 0.6 g tid + CTs	GC + CTX	3 m	0259
Yang, (2016)	11/39	50 (26/24)	43.1 ± 7.2		5.1 ± 1.9y	4.2 ± 2.1y	TGP 0.6 g bid/tid + CTs	GC + CTX	NR	00
Zhu and Wei, (2009)	7/58	65 (35/30)	32 ± 6.5	32 ± 6.5	5m-6y		TGP 0.6 g tid + CTs	GC	3 m	123780
Wang et al. (2013)	6/88	94 (47/47)	43.1	42.8	7.9y	7.4y	TGP 0.6 g tid + CTs	GC	NR	4503

T, test group; C, control group; CTs, control treatments; m, month; y, year; bid, twice a day; tid, three times a day; NR, not reported; GC, glucocorticoids; CTX, cyclophosphamide; TGP, total glucosides of paeony; HCQ, hydroxychloroquine; TAC, tarcolimus; SLEDAI, systemic lupus erythematosus disease activity index; C3, complement 3; C4, complement 4; Ig, Immunoglobulin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ③ SLEDAI; ② C3; ③ C4; ④ IgA; ⑤ IgG; ⑥ IgM; ⑦ ESR; ⑧ CRP; ③ 24 h urine protein; ⑩ GC, average daily dosage; ⑪ cumulative dosage of CTX; @ recurrence rate; ⑬ incidence of adverse reactions.

group and 587 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. Twelve studies (Chen, 2013; Sun, 2013; Xu, 2015; Lin and Liu, 2016; Yang, 2016; Cai et al., 2017; Feng et al., 2017; Peng, 2018; Yu et al., 2019; Li and Zheng, 2020; Xiang, 2020; Xu, 2020) used TGP in combination with GC and CTX. One study (Zhao et al., 2020) used TGP in combination with GC and HCQ. Two studies (Li Z. et al., 2018; Zhang, 2020) used TGP in combination with GC and TAC. Three studies (Zhu and Wei, 2009; Wang and Wang, 2015; Yang and Li, 2019) used TGP in combination with GC. A random-effects model was applied for analysis because of the existence of heterogeneity ($I^2 = 88\%$, p < 0.001). Subgroup analysis showed that the SLEDAI score of the experimental group was significantly lower than that of the control group (SMD = -1.98, 95% Cl = [-2.50, -1.46], *p* <0.001; SMD = -0.65, 95% Cl = [-1.04, -0.26], p < 0.01;SMD = -0.94, 95% Cl = [-1.53, -0.34], p < 0.01;SMD = -1.00, 95% Cl = [-1.64, -0.36], p < 0.01). The difference was statistically significant (Figure 4).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. It was found that two studies (Sun, 2013; Cai et al., 2017) had a significant influence on the result when TGP was combined with GC and CTX treatment. The heterogeneity was reduced after excluding the two articles, (I² = 25% and *p* = 0.21). We merged the data of other studies to analyze (SMD = -2.26, 95% Cl = [-2.52, -2.01], *p* <0.001). The shorter mean duration of disease in patients included in one study (Cai et al., 2017) and the shorter mean disease duration of patients included in another study (Sun, 2013) with more comorbidities and higher disease activity before treatment may be the main reasons for the heterogeneity.

One study (Yang and Li, 2019) had a significant influence on the result when TGP was combined with GC treatment. The heterogeneity was reduced after excluding this study ($I^2 = 0\%$, p =0.66). Data from other studies was merged for analysis (SMD = -0.69, 95% Cl = [-1.08, -0.29], p < 0.001). The older average age of patients in this study may be the main reason for the heterogeneity (Supplementary Figure S1).

3.4.2 C3

Eight studies reported C3 as the outcome, including 316 patients overall in the experimental group and 311 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. Four studies (Sun, 2013; Cai et al., 2017; Yu et al., 2019; Wu et al., 2020) used TGP in combination with GC and CTX. Two studies (Xue and Lyu, 2019; Zhao et al., 2020) used TGP in combination with GC. A fixed-effects model was applied for analysis due to low heterogeneity ($I^2 = 22\%$, p = 0.26). Subgroup analysis showed that C3 in the experimental group was significantly higher than that in the

control group (SMD = 1.28, 95% Cl = [1.05, 1.52], p < 0.001; SMD = 1.43, 95% Cl = [1.09, 1.77], p < 0.001; SMD = 1.12, 95% Cl = [0.74, 1.50], p < 0.001). The difference was statistically significant (Figure 5A).

3.4.3 C4

Six studies reported C4 as the outcome, including 230 patients overall in the experimental group and 225 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. One study (Wu et al., 2020) used TGP in combination with GC and CTX. Two studies (Xue and Lyu, 2019; Zhao et al., 2020) used TGP in combination with GC and HCQ. One study (Li Z. et al., 2018) used TGP in combination with GC and TAC. Two studies (Zhu and Wei, 2009; Yang and Li, 2019) used TGP in combination with GC therapy. A fixed-effects model was applied for analysis because of low heterogeneity ($I^2 = 5\%$, p = 0.39). Subgroup analysis showed that C4 in the experimental group was significantly higher than that in the control group (SMD = 0.87, 95%Cl = [0.40, 1.35], p < 0.001; SMD = 1.43, 95% Cl = [1.08, 1.77],*p* <0.001; SMD = 0.96, 95% Cl = [0.52, 1.40], *p* <0.001; SMD = 1.18, 95% Cl = [0.80, 1.56], p <0.001). The difference was statistically significant (Figure 5B).

3.4.4 IgA

Five studies reported IgA as the outcome, including 215 patients overall in the experimental group and 191 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. One study (Wu et al., 2020) used TGP in combination with GC and CTX. One study (Li Z. et al., 2018) used TGP in combination with GC and HCQ. Three studies (Li, 2013; Liu, 2016; Peng, 2018) used TGP in combination with GC and HCQ. Three studies (Li, 2013; Liu, 2016; Peng, 2018) used TGP in combination with GC. A random-effects model was applied for analysis because of the existence of heterogeneity (I² = 79%, *p* <0.001). Subgroup analysis showed that IgA in the experimental group was lower than that in the control group (SMD = -0.85, 95% Cl = [-1.32, -0.37], *p* <0.001; SMD = -1.45, 95% Cl = [-1.92, -0.99], *p* <0.001; SMD = -0.33, 95% Cl = [-0.57, -0.09], *p* <0.01). The difference was statistically significant (Figure 6A).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. Two studies (Li Z. et al., 2018; Wu et al., 2020) were found to have a significant impact on the result. The heterogeneity was reduced after excluding the two articles ($I^2 = 0\%$, p = 0.77). We merged the data of other studies for analysis (SMD = -0.33, 95% Cl = [-0.57, -0.09], p < 0.01). It was found that TGP in combination with different drug treatments may be responsible for the heterogeneity (Supplementary Figure S2).

3.4.5 IgG

Six studies reported IgG as the outcome, including 267 patients overall in the experimental group and



267 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. Two studies (Sun, 2013; Wu et al., 2020) used TGP in combination with GC and CTX. One study (Li Z. et al., 2018) used TGP in combination with GC and TAC. Three studies (Li, 2013; Wang et al., 2013; Liu, 2016) used TGP in combination with GC. A random-effects model was applied for analysis because of the existence of heterogeneity (I² = 83%, *p* <0.001). Subgroup analysis showed that the IgG in the experimental group was lower than that in the control group (SMD = -0.42, 95% Cl = [-1.60, 0.77], *p* < 0.001; SMD = -1.34, 95% Cl = [-1.80, -0.89], *p* < 0.001; SMD = -0.39, 95% Cl = [-0.63, -0.15], *p* < 0.01). The difference was statistically significant (Figure 6B).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. Three studies (Sun, 2013; Li Z. et al., 2018; Wu et al., 2020) were found to have a significant impact on the result. The heterogeneity was reduced after excluding the three articles ($I^2 = 0\%$, p = 0.82). We merged the data of other studies to analyze (SMD = -0.39, 95% Cl = [-0.63, -0.15], p < 0.01). It was found that TGP in combination with different drug treatments may be responsible for heterogeneity (Supplementary Figure S3).

3.4.6 IgM

Two studies reported IgM as the outcome, including 82 patients overall in the experimental group and 82 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. One study (Wu et al., 2020) used TGP in combination with GC and CTX. One study (Li Z. et al., 2018) used TGP in combination with GC and TAC. A fixed-effects model was applied for analysis because of low heterogeneity (I² = 0%, p = 0.45). Subgroup analysis showed that the IgM in the experimental group was lower than that in the control group (SMD = -1.31, 95% Cl = [-1.81, -0.80], p < 0.001; SMD = -1.05, 95% Cl = [-1.49, -0.61], p < 0.001). The difference was statistically significant (Figure 6C).

3.4.7 ESR

Five studies reported ESR as the outcome, including 155 patients overall in the experimental group and 150 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. Two studies (Cai et al., 2017; Yu et al., 2019) used TGP in combination with GC and CTX. One study (Xue and Lyu, 2019) used TGP in combination with GC and HCQ. Two studies (Zhu and Wei, 2009; Yang and Li, 2019) used TGP in combination with GC. A random-effects model was applied for analysis because of the existence of heterogeneity (I² = 69%, *p* < 0.01). Subgroup analysis showed that the ESR of the experimental group was lower than that in the control group (SMD = -0.95,

	-								
~	Expe	rimen	tal	с.	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 GC+CTX+TGP V	S GC+C	IX							
Cai H 2017	2.41	0.73	30	2.88	0.88	30	5.8%	-0.57 [-1.09, -0.06]	
Chen J 2013	2.3	0.95	21	5.3	2.37	20	5.3%	-1.64 [-2.36, -0.93]	
Feng P 2017	2.1	0.59	27	5.9	2.11	26	5.3%	-2.44 [-3.16, -1.71]	
Li X 2020	2.37	0.61	33	5.73	1.98	33	5.5%	-2.27 [-2.89, -1.64]	
Lin G 2016	2.2	0.93	26	5.1	2.35	25	5.5%	-1.61 [-2.25, -0.97]	
Peng H 2018	2.6	0.6	20	6.3	1.5	20	4.6%	-3.17 [-4.13, -2.21]	
Sun X 2013	5.79	1.15	48	6.37	1.29	48	6.0%	-0.47 [-0.88, -0.07]	
Xiang S 2020	2.14	0.63	35	5.47	1.77	35	5.5%	-2.48 [-3.11, -1.85]	
Xu F 2015	2.1	0.59	27	5.9	2.11	26	5.3%	-2.44 [-3.16, -1.71]	
Xu Y 2020	2.42	0.71	36	5.86	2.15	36	5.6%	-2.13 [-2.71, -1.54]	
Yang M 2016	2.01	0.51	26	6.17	2.34	24	5.2%	-2.47 [-3.21, -1.72]	
Yu H 2019	2.13	0.64	30	5.46	1.78	30	5.4%	-2.46 [-3.14, -1.78]	
Subtotal (95% CI)			359			353	64.9%	-1.98 [-2.50, -1.46]	-
Heterogeneity: Tau ² = Test for overall effect:	0.74; Cl Z = 7.40	hi² = 90 1 (P < 0	0.43, df 0.00001	í = 11 (P)	o < 0.01 × ۱	0001); I	²= 88%		
1.1.2 GC+HCQ+TGP V	S GC+H	CQ							
Zhao L2020	4.75	1.93	53	6.08	2.13	53	6.1%	-0.65 [-1.04, -0.26]	-
Subtotal (95% CI)			53			53	6.1%	-0.65 [-1.04, -0.26]	•
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 3.26	(P = 0	.001)						
1.1.3 GC+Tac+TGP V	S GC+Ta	ic							
Li Z 2018	4.81	1.65	45	6.16	2.36	45	6.0%	-0.66 [-1.08, -0.23]	
Zhang Y 2020	4.75	1.02	32	6.17	1.19	32	5.7%	-1.27 [-1.81, -0.73]	
Subtotal (95% CI)			77			77	11.7%	-0.94 [-1.53, -0.34]	•
Heterogeneity: Tau ² = Test for overall effect:	0.12; CI Z = 3.09	hi² = 3. I (P = 0	01, df= 1.002)	= 1 (P =	0.08);	l² = 679	Х6		
44400-100-00									
1.1.4 GC+TGP VS GC	0.00	4 77	4	1.74	4 70	24	C . C . V	0.0014.00.0.00	
Wang D 2015	3.66	1.11	21	4.71	1.79	21	5.5%	-0.58 [-1.20, 0.04]	
Yang X 2019 750 Y 2000	4.33	1.19	53	0.84	1.87	53	5.0%	-1.59 [-2.03, -1.15]	
Zhu Y 2009 Subtetel (05% CI)	12	4.8	35	16	5.68	30	5.8%	-0.76[-1.26, -0.25]	
Hotorogonalty Tav?	0.25.00	hiZ - C	20 46	2/0-	0.04 0	104	17.5%	- 1.00 [- 1.04, -0.36]	-
Test for overall effect:	Z = 3.05	(P = 0	28, ui - 1.002)	= 2 (F =	0.010,	, = 70	570		
Total (95% Cl)			598			587	100.0%	-1.60 [-1.99, -1.22]	•
Heterogeneity: Tau ² =	0.59° CI	hi ² = 14	40.21	df = 17 (P < 0	00001	² = 88%	,,	
Test for overall effect	Z = 8.20	(P < 0	00001)					-4 -2 0 2 4
Test for subaroup diff	erences	: Chi² =	= 16.24	. df = 3	(P = 0.	001). I ^a	= 81.5%		experimental control
TOTOST PLOT OF SELDAI.									

95% Cl = [-1.73, -0.17], p < 0.05; SMD = -1.77, 95% Cl = [-2.37, -1.17], p < 0.001; SMD = -1.58, 95% Cl = [-1.98, -0.17], p < 0.001). The difference was statistically significant (Figure 7A).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. It was found that one study (Yu et al., 2019) had an important impact on the result. The heterogeneity was reduced after excluding this article (I² = 0%, p = 0.63). We merged the data of other studies to analyze (SMD = -1.56, 95% Cl = [-1.85, -1.27], p < 0.001). The imprecise result of the study may be the main reason for the heterogeneity. (Supplementary Figure S4).

3.4.8 CRP

Two studies reported CRP as the outcome, including 65 patients overall in the experimental group and 60 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. One study (Yu et al., 2019) used TGP in combination with GC and CTX. One study (Zhu and Wei, 2009) used TGP in combination with GC. A fixed-effects model was applied for analysis because of low heterogeneity (I² = 11%, *p* = 0.29). Subgroup analysis showed that the CRP of the experimental group was lower than that of the control group (SMD = -1.01, 95% Cl = [-1.55, -0.47], *p* <0.001; SMD = -0.61, 95% Cl = [-1.11, -0.11], *p* < 0.05). The difference was statistically significant (Figure 7B).

Α									
	Expe	riment	tal	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.2.1 GC+CTX+TGP	/S GC+C1	TX							
Cai H 2017	1.23	0.33	30	0.91	0.26	30	10.2%	1.06 [0.52, 1.61]	
Sun X 2013	0.79	0.22	48	0.37	0.29	48	14.0%	1.62 [1.16, 2.08]	
Wu X 2020	0.83	0.27	37	0.6	0.25	37	13.2%	0.87 [0.40, 1.35]	
Yu H 2019	1.28	0.25	53	0.94	0.21	53	16.2%	1.46 [1.03, 1.89]	
Subtotal (95% CI)			168			168	53.6%	1.28 [1.05, 1.52]	◆
Heterogeneity: Chi ² =	: 6.11, df:	= 3 (P =	= 0.11)	; I² = 51	%				
Test for overall effect	Z=10.6	2 (P <	0.0000	1)					
1.2.2 GC+HCQ+TGP	VS GC+H	CQ							
Xue Y2019	1.27	0.24	30	0.95	0.22	30	9.4%	1.37 [0.81, 1.94]	
Zhao L2020	1.28	0.25	53	0.94	0.21	53	16.2%	1.46 [1.03, 1.89]	
Subtotal (95% CI)			83			83	25.6%	1.43 [1.09, 1.77]	•
Heterogeneity: Chi ² =	: 0.06, df :	= 1 (P =	= 0.80)	; I ² = 0%	5				
Test for overall effect	: Z = 8.18	(P < 0	.00001)					
1.2.3 GC+TGP VS GC									
Yang X 2019	1.27	0.24	30	0.95	0.22	30	9.4%	1.37 [0.81, 1.94]	
Zhu Y 2009	1.12	0.39	35	0.76	0.39	30	11.4%	0.91 [0.40, 1.43]	
Subtotal (95% CI)			65			60	20.8%	1.12 [0.74, 1.50]	•
Heterogeneity: Chi ² =	: 1.39, df :	= 1 (P =	= 0.24)	; I ² = 28	%				
Test for overall effect	: Z = 5.77	(P < 0	.00001)					
Total (95% CI)			316			311	100.0%	1.29 [1.11, 1.46]	
Heterogeneity: Chi ² =	: 8.97, df :	= 7 (P =	= 0.26)	; I² = 22	%			-4	-2 0 2 4
Test for overall effect	: Z = 14.5	4 (P <	0.0000	1)				-4	experimental control
Test for subaroup di	Terences:	: Chi²=	= 1.40.	df = 2 (F	P = 0.5	0). I² =	0%		separation and control

В

	Expe	erimen	tal	С	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
1.3.1 GC+CTX+TGP VS	GC+C	TX							
Wu X 2020	0.27	0.1	37	0.19	0.08	37	17.5%	0.87 [0.40, 1.35]	-
Subtotal (95% CI)			37			37	17.5%	0.87 [0.40, 1.35]	•
Heterogeneity: Not app	plicable								
Test for overall effect: 2	Z = 3.58	8 (P = 0	1.0003)						
1.3.2 GC+HCQ+TGP V	S GC+H	CQ							
Xue Y2019	0.31	0.06	30	0.24	0.05	30	12.9%	1.25 [0.69, 1.81]	
Zhao L2020	0.32	0.05	53	0.25	0.04	53	21.2%	1.53 [1.10, 1.97]	
Subtotal (95% CI)			83			83	34.1%	1.43 [1.08, 1.77]	•
Heterogeneity: Chi ² = 0	0.62, df	= 1 (P	= 0.43)	; I ² = 09	6				
Test for overall effect: 2	Z = 8.16	6 (P < 0	0.00001)					
1.3.3 GC+Tac+TGP VS	GC+Ta	ic							
Li Z 2018	0.19	0.05	45	0.15	0.03	45	20.9%	0.96 [0.52, 1.40]	-
Subtotal (95% CI)			45			45	20.9%	0.96 [0.52, 1.40]	•
Heterogeneity: Not app	plicable								
Test for overall effect: 2	Z = 4.31	(P < 0	1.0001)						
1.3.4 GC+TGP VS GC									
Yang X 2019	0.31	0.06	30	0.24	0.05	30	12.9%	1.25 [0.69, 1.81]	
Zhu Y 2009	0.52	0.22	35	0.33	0.07	30	14.5%	1.11 [0.59, 1.64]	
Subtotal (95% CI)			65			60	27.4%	1.18 [0.80, 1.56]	•
Heterogeneity: Chi ² = (0.12, df	= 1 (P	= 0.73)	; I ² = 09	6				
Test for overall effect: 2	Z = 6.04	(P < 0	0.00001)					
Total (95% CI)			230			225	100.0%	1.16 [0.96, 1.36]	•
Heterogeneity: Chi ² = 9	5.24, df	= 5 (P	= 0.39)	; I ² = 59	6				
Test for overall effect: 2	Z = 11.4	0 (P <	0.0000	01)					evperimental control
Test for subaroup diffe	erences	: Chi ² =	= 4.50.	df = 3 (f	P = 0.2	1), ² =	33.4%		systemental sention
FIGURE 5									
Forest plot of C3 (A), C4	(B).								

•									
A	Expe	erimen	tal	с	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.4.1 GC+CTX+TGP \	/S GC+C	ТХ							
Wu X 2020	2.57	0.54	37	3.04	0.56	37	19.2%	-0.85 [-1.32, -0.37]	
Subtotal (95% CI)			37			37	19.2%	-0.85 [-1.32, -0.37]	◆
Heterogeneity: Not a	pplicable								
Test for overall effect	Z = 3.48	(P=0	1.0005)						
1.4.2 GC+Tac+TGP V	S GC+Ta	IC							
Li Z 2018	2.12	0.43	45	2.82	0.52	45	19.4%	-1.45 [-1.92, -0.99]	T
Subtotal (95% CI)			45			45	19.4%	-1.45 [-1.92, -0.99]	-
Heterogeneity: Not a	pplicable								
Test for overall effect	Z = 6.11	(P < 0	0.00001)					
44200,00000000000									
1.4.3 GC+1GP VS GC	2.07	2.26	47	2 70	2 00	47	20.60	0 27 1 0 67 0 1 41	
LIT 2013	3.07	1.30	47	3.70	2.00	47	20.0%	-0.27 [-0.07, 0.14]	
LIU VV 2010	2.00	1.35	43	3.91	2.9	43	20.2%	-0.40 [-0.09, -0.03]	
Subtotal (05% CI)	3.07	2.50	137	3.70	2.00	137	61 3%	0.27 [-0.07, 0.14]	•
Unteregeneiter Tou?	0.00.0	hiz - 0	EA df-	- 2/0 -	0 771	137	01.5%	-0.55 [-0.57, -0.05]	•
Test for everall effect	7 - 2 60	n = 0	.94, ui =	= 2 (F =	0.77),	1-= 0 %			
restion overall ellect	. <u>2</u> = 2.08	(r = t	.007)						
Total (95% CI)			219			219	100.0%	-0.65 [-1.08, -0.22]	•
Heterogeneity: Tau ² :	= 0.19 ⁻ C	hi² = 1!	9 4 4 dt	(= 4 (P :	= 0 000	16): 17=	79%	the [hoo, one]	
Test for overall effect	7 = 2.96	(P = f)	003	. (0.000				-4 -2 0 2 4
Test for subgroup dif	ferences	Chi ²	= 18.91	df = 2	(P < 0	0001)	$ ^2 = 89.49$	6	experimental control

в

	Exp	eriment	al	(Control			Std. Mean Difference	Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl			
1.5.1 GC+CTX+TGP V	S GC+C	TX										
Sun X 2013	15.41	1.27	48	15.15	1.57	48	17.1%	0.18 [-0.22, 0.58]				
Wu X 2020	12.14	2.53	37	14.89	2.75	37	15.9%	-1.03 [-1.52, -0.54]				
Subtotal (95% CI)			85			85	33.0%	-0.42 [-1.60, 0.77]	-			
Heterogeneity: Tau ² =	= 0.68; CI	hi ² = 14.	16, df =	= 1 (P =	0.0002); I ² = 9:	3%					
Test for overall effect:	Z = 0.69	(P = 0.4	49)									
4.5.0.00.7	0.00.7-											
1.5.2 GC+Tac+TGP V	S GC+Ta	IC							-			
Li Z 2018	14.02	2.41	45	17.13	2.17	45	16.3%	-1.34 [-1.80, -0.89]				
Subtotal (95% CI)			45			45	16.3%	-1.34 [-1.80, -0.89]	-			
Heterogeneity: Not ap	oplicable											
Test for overall effect:	Z= 5.74	(P < 0.0	00001)									
1.5.3 GC+TGP VS GC												
Li Y 2013	18.34	11.16	47	22.18	11.27	47	17.0%	-0.34 [-0.75, 0.07]				
Liu W 2016	17.23	10.84	43	23.08	12.16	43	16.7%	-0.50 (-0.93, -0.07)				
Wang Z 2013	18.34	11.16	47	22.18	11.27	47	17.0%	-0.34 [-0.75, 0.07]				
Subtotal (95% CI)			137			137	50.7%	-0.39 [-0.63, -0.15]	•			
Heterogeneity: Tau ² =	= 0.00: CI	hi² = 0.3	8. df =	2(P = 0)).82): I ² :	= 0%		•				
Test for overall effect:	Z = 3.20	(P = 0.0	001)									
Total (05% CI)			267			267	100.0%	0.551.0.09 0.121				
Total (95% CI)	0.04.01		207	C (D)	0.0004	207	100.0%	-0.55 [-0.98, -0.12]	→			
Heterogeneity: Tau*=	= 0.24; CI	nr= 29.	80, df :	= 5 (P <	0.0001); i* = 8:	5%		-4 -2 0 2 4			
Test for overall effect:	Z = 2.53	(P = 0.0)	J1)						experimental control			
Test for subaroup dif	terences	: Chi ² =	13.12.	dt = 2 (P = 0.00	11), l ² =	84.8%					

С

	Experimental				С	ontrol			Std. Mean Difference	Std. Mean Difference			
_	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl			
	1.6.1 GC+CTX+TGP V	S GC+C	TX										
	Wu X 2020	1.83	0.3	37	2.24	0.32	37	43.4%	-1.31 [-1.81, -0.80]				
	Subtotal (95% CI)			37			37	43.4%	-1.31 [-1.81, -0.80]	•			
	Heterogeneity: Not ap	plicable											
	Test for overall effect:	Z = 5.08	8 (P < 0	.00001)								
	162GC+Tac+TGPV	S 6C+T2	10										
	117 2018	1 46	0.27	45	1 78	0.33	45	56.6%	-1 05 61 49 -0 611				
	Subtotal (95% CI)	1.40	0.21	45	1.10	0.00	45	56.6%	-1.05 [-1.49, -0.61]	▲			
	Heterogeneity: Not ap	plicable							,,				
	Test for overall effect:	Z = 4.67	(P < 0	.00001)								
	Total (95% CI)			82			82	100.0%	-1.16 [-1.50, -0.83]	•			
	Heterogeneity: Chi ² =	0.56, df	= 1 (P	= 0.45)	; l² = 09	6				-4 -2 0 2 4			
	Test for overall effect:	Z = 6.88	6 (P < 0	.00001)					experimental control			
	Test for subaroup diff	erences	: Chi ² :	= 0.56.	df = 1 (P = 0.4	5), ² =	0%					
FIGURE 6													
Forest plot of	lgA (A) , lgG (B) , lg	дМ (С)											

Α	Eve	orimont	al		ontrol			Std. Maan Difference	Std Moon Difference
Study or Subgroup	Moan	SD	Total	Moan		Total	Moight	N Pandom 95% Cl	N Pandom 95% Cl
171GC+CTX+TGD	/S GC+C	<u>30</u> TX	Total	Wean	30	Total	weight	TV, Random, 55% Ci	
Coi H 2017	22.24	1 50	20	20.25	4 21	20	20.0%	1 26 [1 02 .0 70]	
	10.42	4.30	20	25.55	4.31	20	20.0%	-0.56[-1.02,-0.73]	
Subtotal (95% CI)	15.45	10.75	60	23.07	11.54	60	41 2%	0.05[173_047]	•
Hotorogeneity Tou?	- 0.24: 0	hi² - 1 1	9 df-	1 /P - 0	041-12-	- 76%	41.270	-0.55 [-1.75, -0.17]	•
Test for overall effect	7 = 2.39	P = 0.1	0, 01 -	1 (1 - 0		- 70 %			
restion overall ellect		, (i = 0.i	02)						
1.7.2 GC+HCQ+TGP	VS GC+H	CQ							
Xue Y2019	18.02	4.37	30	26.35	4.9	30	19.2%	-1.77 [-2.37, -1.17]	
Subtotal (95% CI)			30			30	19.2%	-1.77 [-2.37, -1.17]	◆
Heterogeneity: Not a	pplicable								
Test for overall effect	: Z = 5.76	6 (P < 0.0	00001)						
1736C+T6P VS 60									
Yang X 2019	18.02	4 37	30	26 35	49	30	19 7%	-1 77 [-2 37 -1 17]	
7hu Y 2009	35.08	813	35	45.98	6 96	30	20.4%	-1 41 [-1 96 -0 87]	-
Subtotal (95% CI)	55.00	0.10	65	40.00	0.00	60	39.6%	-1.58 [-1.98, -1.17]	•
Heterogeneity Tau ² :	= 0.00° C	$hi^2 = 0.7$	3 df=	1 (P = 0)	(39) P	= 0%			
Test for overall effect	7 = 7.61	(P < 0)	00001						
			,						
Total (95% CI)			155			150	100.0%	-1.36 [-1.81, -0.91]	•
Heterogeneity: Tau ² :	= 0.18; C	hi ² = 12.	80, df:	= 4 (P =	0.01); P	= 69%			
Test for overall effect	Z = 5.88	(P < 0.0	00001)						-4 -2 U 2 4
Test for subaroup dit	fferences	: Chi ² =	2.79.0	f= 2 (P	= 0.25).	I ² = 28	.2%		experimental control

В

	Expe	rimen	tal	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
1.8.1 GC+CTX+TGP V	S GC+C	ГХ							
Yu H 2019	9.37	4.82	30	13.52	3.14	30	46.2%	-1.01 [-1.55, -0.47]	
Subtotal (95% CI)			30			30	46.2%	-1.01 [-1.55, -0.47]	◆
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 3.66	(P = 0	.0003)						
1.8.2 GC+TGP VS GC Zhu Y 2009 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect:	25 oplicable Z = 2.39	6.08 (P = 0	35 35 1.02)	29.01	6.95	30 30	53.8% 53.8 %	-0.61 [-1.11, -0.11] -0.61 [-1.11, -0.11]	*
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect: Test for subdroup diff	1.12, df Z = 4.24 ferences	= 1 (P (P < 0 : Chi ² :	65 = 0.29) 1.0001) = 1.12.	; ² = 11 df = 1 (F	% P = 0.2	60 9). I² =	100.0 %	-0.79 [-1.16, -0.43]	-4 -2 0 2 4 experimental control

С

	•	Expe	erimen	tal	C	ontrol			Std. Mean Difference	Std. Mean Difference		
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
	Cai H 2017	1.34	0.53	30	1.39	0.62	30	11.2%	-0.09 [-0.59, 0.42]			
	Chen J 2013	1.37	0.74	21	1.66	0.85	20	7.5%	-0.36 [-0.98, 0.26]			
	Feng P 2017	0.56	0.15	48	0.66	0.02	48	16.1%	-0.93 [-1.35, -0.51]	-		
	Li X 2020	1.21	0.54	33	1.83	0.61	33	10.7%	-1.06 [-1.58, -0.55]			
	Lin G 2016	1.35	0.72	26	1.63	0.82	25	9.4%	-0.36 [-0.91, 0.20]			
	Peng H 2018	1.31	0.03	20	1.8	0.79	20	6.8%	-0.86 [-1.51, -0.21]			
	Sun X 2013	1.15	0.53	26	1.96	0.82	24	7.9%	-1.16 [-1.77, -0.56]			
	Xiang S 2020	1.28	0.65	27	1.81	0.77	26	9.2%	-0.73 [-1.29, -0.18]			
	Xu F 2015	1.18	0.65	27	1.88	0.77	26	8.8%	-0.97 [-1.54, -0.40]			
	Xu Y 2020	1.26	0.51	36	1.76	0.72	36	12.4%	-0.79 [-1.27, -0.31]			
	Total (95% CI)			294			288	100.0%	-0.73 [-0.90, -0.57]	•		
	Heterogeneity: Chi ² =	14.67, d	lf = 9 (F	P = 0.10	0); I² = 3	9%				-4 -2 0 2 4		
	Test for overall effect:	Z = 8.50) (P < 0	.00001)					experimental control		
FIGURE 7	7											
Forest pla	ot of ESR (A) , CRP (B) , 24h	n urine	e prot	ein (C)).						

Unty of Subgroup Mean SD Total Weight M. Bandom, 95% CI W. Random, 95% CI 10.1 GC+CTX+TGP VS GC+CTX 12.3 3.57 21 2.32 3.73 20 6.18 -0.55 [+1.07, -0.04] -0.55 [+1.07, -0.04] hen J 2013 12.3 3.57 21 2.32 3.73 20 6.18 -2.77 [+3.65, -1.88]	A	Expe	riment	al	C	ontrol			Std. Mean Difference	Std. Mean Difference	
101 + G - CTX + TGP VS - GC + CTX is all + 36 3.68 30 8.8% - 0.55 [+ 107, -0.04] + 100	tudy or Subaroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random. 95% CI	IV, Random, 95% Cl	
$\frac{a_{11} + 2017}{1224} \frac{1}{254} \frac{1}{254} \frac{1}{254} \frac{1}{254} \frac{1}{212} \frac{1}{2254} \frac{1}{2554} \frac{1}{2554} \frac{1}{2554} \frac{1}{2556} \frac{1}{2556} \frac{1}{2566$.10.1 GC+CTX+TGP	VS GC+	CTX								
$\frac{1}{10^{2}} \frac{1}{10^{2}} \frac{1}{10^{2}} \frac{1}{10^{2}} \frac{1}{22^{2}} \frac{1}{23^{2}} 1$	ai H 2017	12.34	3.51	30	14.36	3.68	30	8.8%	-0.55 [-1.07, -0.04]	-	
$\frac{enp}{2} 2017$ 116 221 27 241 344 26 80% -370 445 -2719 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4	Chen J 2013	12.3	3.97	21	23.2	3.73	20	8.1%	-2.77 [-3.65, -1.89]		
$ \begin{array}{c} yx 2020 \\ yx 2020 \\ yx 2020 \\ yx 201 \\ yx 201 \\ yx 201 \\ yx 202 \\ yx 201 \\ yx 202 \\ y$	eng P 2017	11.6	3.21	27	24.1	3 4 4	26	8.0%	-3 70 [-4 61 -2 79]		
$\frac{\ln 3 016}{\ln 3 2016} = \frac{122}{122} \frac{2}{395} \frac{2}{28} \frac{2}{31} \frac{3}{372} \frac{2}{25} \frac{2}{8} \frac{3}{38} \frac{-2}{-280[358,201]} + \frac{1}{168} \frac{1}{321} \frac{1}{372} \frac{1}{285} \frac{1}{295} $	i X 2020	1214	3.09	33	25.23	2.78	33	8.0%	-4 40 [-5 31 -3 49]	—	
$\frac{1}{3} + 2016 \\ \frac{1}{159} + 2016 \\ \frac{1}{159} + 225 \\ \frac{1}{220} + 227 \\ \frac{1}{38} + 20 \\ \frac{1}{220} + 227 \\ \frac{1}{38} + 235 \\ \frac{1}{320} + 228 \\ \frac{1}{38} + 223 \\ \frac{1}{38} + 223 \\ \frac{1}{38} + 224 \\ \frac{1}{304} + 228 \\ \frac{1}{38} + 228 \\ \frac{1}{38} + 228 \\ \frac{1}{38} + 228 \\ \frac{1}{38} + 223 \\ \frac{1}{38} + 238 \\ \frac{1}{38} + 238 \\ \frac{1}{38} + 238 \\ \frac{1}{39} + 238 \\ \frac{1}{38} + 238 \\ \frac{1}{39} $	in G 2016	12.2	3.95	26	23.1	3.72	25	8.3%	-2.80 [-3.58, -2.01]		
$\frac{1}{4} = 32020$ $\frac{11}{150} = 328 = 326 = 231 = 323 = 356 = 231 = 323 = 356 = 94.\% - 316 + 331 + 24.7 = 14.8 + $	Peng H 2018	11.8	2.5	20	22.7	3.8	20	7.8%	-3.32 [-4.31, -2.34]		
$ \frac{1}{2} 2015 \\ \frac{1}{2} 115 \\ \frac{1}{2} 216 \\ \frac{1}{2} 21 \\ \frac{1}{2} 26 \\ \frac{1}{2} 21 \\ \frac{1}{2} 26 \\ \frac{1}{2} 21 \\ \frac{1}{2} 26 \\ \frac{1}{2} 21 \\ \frac{1}{2} 2 \\ \frac{1}{2} 2 \\ \frac{1}{2} \\ \frac{1}{2$	(iang S 2020	11.59	3.28	35	23.1	3.83	35	8.4%	-3.19 [-3.91, -2.47]		
$ \begin{array}{c} u^{v} 2020 & 11.23 & 2.85 & 38 & 22.19 & 4.27 & 38 & 8.5\% & -2.98 (3.87, -2.30) \\ util 2019 & 11.58 & 3.29 & 30 & 23.09 & 3.84 & 30 & 8.3\% & -3.18 (3.85, -2.40) \\ util 2019 & 11.64 & 2.48 & 45 & 22.39 & 3.02 & 45 & 8.8\% & -2.13 (3.85, -2.40) \\ util 2019 & 16.45 & 2.48 & 45 & 22.39 & 3.02 & 45 & 8.8\% & -2.13 (2.65, -1.61) \\ util 2019 & 16.45 & 2.48 & 45 & 22.39 & 3.02 & 45 & 8.8\% & -2.13 (2.65, -1.61) \\ util 2019 & 16.45 & 2.48 & 45 & 22.39 & 3.02 & 45 & 8.8\% & -2.13 (2.65, -1.61) \\ util 2019 & 16.45 & 2.48 & 45 & 22.29 & 1.6 & 30 & 8.8\% & -0.94 (-1.46, -0.43) \\ util 2019 & 13.4 & 7.3 & 35 & 22.5 & 11.6 & 30 & 8.8\% & -0.94 (-1.46, -0.43) \\ util 2019 & 13.4 & 7.3 & 35 & 22.5 & 11.6 & 30 & 8.8\% & -0.94 (-1.46, -0.43) \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2019 & 13.4 & 7.3 & 35 & 356 & 100.0\% \\ util 2017 & 8.79 & 0.63 & 30 & 9.23 & 0.78 & 30 & 10.4\% & -0.61 (-1.13, -0.09) \\ util 2017 & 8.79 & 0.63 & 30 & 9.23 & 0.78 & 30 & 10.4\% & -0.61 (-1.13, -0.09) \\ util 2017 & 1.42 & 1.24 & 27 & 18.1 & 2.13 & 26 & 9.8\% & -3.40 (-1.48, -7.52) \\ util 2020 & 2.21 & 1.12 & 33 & 19.22 & 2.1 & 33 & 9.9\% & -9.68 (-1.13, -7.23) \\ util 2017 & 1.42 & 1.24 & 27 & 18.1 & 2.13 & 26 & 9.8\% & -9.48 (-1.14, -7.52) \\ util 2016 & 1.64 & 0.83 & 26 & 9.7 & 0.72 & 25 & 9.6\% & -9.28 (-1.13, -7.23) \\ util 2016 & 1.64 & 0.83 & 26 & 9.7 & 0.72 & 25 & 9.6\% & -9.38 (-1.32, -7.52) \\ util 2016 & 1.64 & 0.83 & 26 & 9.7 & 0.72 & 25 & 9.6\% & -9.38 (-1.32, -7.52) \\ util 2019 & 1.44 & 0.47 & 30 & 9.05 & 1.38 & 30 & 10.1\% & -5.90 (-1.23, -5.53) \\ util 2019 & 1.44 & 0.47 & 30 & 9.05 & 1.38 & 30 & 10.1\% & -5.90 (-1.23, -5.53) \\ util 2019 & 1.44 & 0.47 & 30 & 9.05 & 1.38 & 30 & 10.1\% & -5.90 (-1.2, -5.53) \\ util 2019 & 1.44 & 0.47 & $	(u F 2015	11.6	3.21	27	24.1	3.44	26	8.0%	-3.70 [-4.61, -2.79]		
u H 2019 11.58 3.29 30 23.09 3.84 30 8.3% -3.18 [3.36]; 2.40] withotal (95% CI) 285 281 82.4% -3.04 [-3.83, -2.24] est for overall effect Z = 7.46 (P < 0.00001); P = 90% est for overall effect Z = 7.46 (P < 0.00001) .10.2 GC+Tac+TGP VS GC+Tac 12 2018 16.45 2.48 45 22.39 3.02 45 8.8% -2.13 [2.65, -1.61] withotal (95% CI) 16.45 2.48 45 22.39 3.02 45 8.8% -2.13 [2.65, -1.61] withotal (95% CI) 13.4 7.3 35 22.5 11.6 30 8.8% -0.94 [-1.46, -0.43] withotal (95% CI) 35 30 8.8% -0.94 [-1.46, -0.43] withotal (95% CI) 35 365 10.0% -2.77 [-3.48, -2.06] Herogeneity: Not applicable est for overall effect Z = 7.64 (P < 0.00001); P = 90.6% 3 3 3 3 3 3 3 3 3 3 3 3 3	(u Y 2020	11.23	2.85	36	22.19	4.27	36	8.5%	-2.99 [-3.67, -2.30]	-	
ubtotal (95% Cl) 285 281 82.4% $-3.04 [-3.83, -2.24]$ leterogeneity: Tau ² = 1.48; Chi ² = 9.4.57, df = 9 ($P < 0.00001$); P = 90% est for overall effect Z = 7.4 ($P < 0.00001$) .10.2 GC+Tac-TGP VS GC+Tac IZ 2018 16.45 248 45 22.39 3.02 45 8.8% $-2.13 [-2.65, -1.61]$ ubtotal (95% Cl) 45 45 8.8% $-2.13 [-2.65, -1.61]$ est for overall effect Z = 8.01 ($P < 0.00001$) .10.3 GC+TGP VS GC ubtotal (95% Cl) 35 30 8.8% $-0.94 [-1.46, -0.43]$ ubtotal (95% Cl) 365 356 100.0% est for overall effect Z = 7.64 ($P < 0.00001$) est for overall effect Z = 7.64 ($P < 0.00001$) est for subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% 3 Experimental Control tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 21.37, df = 2 ($P < 0.0001$), P = 90.6% Std. Mean Difference tudy or Subaroup differences: Chi ² = 1.23, 26, 9.8%, -9.44 [-1.143, -7.62] t = 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,	'u H 2019	11.58	3.29	30	23.09	3.84	30	8.3%	-3.18 [-3.95, -2.40]		
leterogeneity: Tau ² = 1.42; Ch ² = 96 < 0.00001); P = 90% est for overall effect Z = 7.46 (P < 0.00001) :10.2 GC+Tac+TGP VS GC+Tac I2 2018 16.45 2.48 45 22.39 3.02 45 8.8% -2.13 [-2.65, -1.61] ubtotal (95% Cl) 16.4 2.48 45 22.39 3.02 45 8.8% -2.13 [-2.65, -1.61] ubtotal (95% Cl) 17.4 5 45 45 2.25 11.6 30 8.8% -0.94 [-1.46, -0.43] ubtotal (95% Cl) 35 36 100.0% est for overall effect Z = 3.59 (P = 0.0003) otal (95% Cl) 365 356 100.0% est for overall effect Z = 7.64 (P < 0.00001); P = 92% est for overall effect Z = 7.64 (P < 0.00001) est for subaroup differences: Ch ² = 21.37. df = 2 (P < 0.0001). P = 90.8% 3 3 3 3 3 3 3 3 3 3 3 3 3	Subtotal (95% CI)			285			281	82.4%	-3.04 [-3.83, -2.24]	◆	
est for overall effect $Z = 7.46 (P < 0.00001)$ 10.2 GC+Tac+TGP VS GC+Tac 12 2018 16.45 2.48 45 22.39 3.02 45 8.8% -2.13 [-2.65, -1.61] 12 018 16.45 2.48 45 22.39 3.02 45 8.8% -2.13 [-2.65, -1.61] 12 018 16.45 2.48 45 22.39 3.02 45 8.8% -2.13 [-2.65, -1.61] 14 017 8.70 VS GC 10 36 C+TGP VS GC 10 30 GC+TGP VS GC 10 10 45 12 8.01 (P < 0.00001) 10.3 GC+TGP VS GC 10 10 45 12 8.01 (P < 0.00001) 10.3 GC+TGP VS GC 10 10 45 12 8.01 (P < 0.00001) 10.3 GC+TGP VS GC 10 10 45 12 8.01 (P < 0.00001) 10 35 35 356 100.0% 10 10 45 12 8.8% -0.94 [-1.46, -0.43] 10 10 45 12 8.8% 10 10 45 12 8.8% 10 10 45 12 8.8% 10 10 10 10 10 10 10 10 10 10 10 10 10 1	leterogeneity: Tau ² =	1.48; CI	hi² = 94	.57, df	= 9 (P <	< 0.000	001); I ²	= 90%			
$\frac{10.2 \text{ GC} + \text{Tac} + \text{TGP VS GC} + \text{Tac}}{12 2018 16.45 2.48 45 22.39 3.02 45 8.8\% -2.13 [-2.65, -1.61] + \frac{1}{2.205} + $	est for overall effect:	Z=7.46	(P < 0	.00001)						
I = 2018 16.45 248 45 22.38 3.02 45 8.8% -2.13 [+2.65, -1.61] + I = I + I + I + I + I + I + I + I + I	.10.2 GC+Tac+TGP	VS GC+T	ac								
ubutotal (95% C) 45 45 8.8% -2.13 [-2.65, -1.61] leterogeneity: Not applicable est for overall effect. $Z = 8.01 (P < 0.00001)$.10.3 GC+TGP VS GC hu Y 2009 13.4 7.3 35 22.5 11.6 30 8.8% -0.94 [-1.46, -0.43] ubtotal (95% C) 35 30 8.8% -0.94 [-1.46, -0.43] ubtotal (95% C) 365 356 100.0% -2.77 [-3.48, -2.06] est for overall effect. $Z = 3.59 (P = 0.0003)$ otal (95% C) 365 356 100.0% -2.77 [-3.48, -2.06] .10 -5 0 5 10 est for overall effect. $Z = 7.64 (P < 0.00001)$; $P = 92\%$ est for overall effect. $Z = 7.64 (P < 0.00001)$; $P = 90.6\%$ 3 3 3 3 3 3 3 3 3 3 3 3 3	.i Z 2018	16.45	2.48	45	22.39	3.02	45	8.8%	-2.13 [-2.65, -1.61]	T	
leterogeneity: Not applicable est for overall effect: $Z = 8.01 (P < 0.0001)$.t0.3 GC+TGP VS GC huły 2009 13.4 7.3 35 22.5 11.6 30 8.8% -0.94 [-1.46, -0.43] ubtotal (95% C) 35 30 8.8% -0.94 [-1.46, -0.43] .eterogeneity: Not applicable est for overall effect: $Z = 3.59 (P = 0.0003)$ otal (95% C) 365 356 100.0% leterogeneity: Tau ² = 1.42; Chi ² = 130.96, df = 11 (P < 0.0001); P = 92% est for overall effect: $Z = 7.64 (P < 0.0001)$ leterogeneity: Tau ² = 1.42; Chi ² = 130.96, df = 11 (P < 0.0001); P = 90.6% 3 3 3 5 5 5 5 5 5 5 5 5 5	Subtotal (95% CI)			45			45	8.8%	-2.13 [-2.65, -1.61]	•	
est for overall effect. Z = 8.01 ($P < 0.00001$) .10.3 GC+TGP VS GC hu Y 2009 13.4 7.3 35 22.5 11.6 30 8.8% -0.94 [1.46, -0.43] eterogeneity. Not applicable est for overall effect. Z = 3.59 ($P = 0.0003$) otal (95% CI) 365 356 100.0% est for overall effect. Z = 4.64 ($P < 0.00001$); $P = 92\%$ est for overall effect. Z = 4.64 ($P < 0.00001$); $P = 92\%$ est for overall effect. Z = 6.46 ($P < 0.00001$) est for overall effect. Z = 6.46 ($P < 0.00001$); $P = 90.6\%$ 3 S S Experimental Control Std. Mean Difference tudy or Subgroup Mean SD Total Mean SD Total Weight M. (N. Random, 95% CI in G 2016 1.64 0.83 26 9.7 0.72 25 9.6% -0.20 [1.13, -0.09] in G 2016 1.64 0.83 26 9.7 0.72 25 9.6% -0.20 [1.13, -7.52] eng P 2017 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [1.13, -7.52] eng P 2017 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [1.13, -7.52] eng P 2018 1.4 1.3 20 18 2.1 20 9.5% -9.32 [1.15, -7.08] in G 2016 1.64 0.83 26 9.7 0.72 25 9.6% -10.20 [1.23, -8.07] eng H 2018 1.4 1.3 20 18 2.1 20 9.5% -9.32 [1.15, -7.08] u Y 2020 0.65 2 9.06 63 1.01 (4.25 3.46 63 61 0.04 (4.3 -3.01 [-3.7, -5.2] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.13, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.37, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.37, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.37, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u Y 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [+1.43, -7.52] u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 [-8.28, -5.53] eterogeneity: Tau ² = 13.06; Chi ² = 355.69, df = 9 ($P < 0.00001$); $P = 97\%$ est for overall effect. Z = 5.86 ($P < 0.00001$); $P = 97\%$ est for overall effect. Z = 5.86 ($P < 0.00$	leterogeneity: Not ap	plicable									
$\frac{10.3 \text{ GC} + \text{TGP VS GC}}{100000000000000000000000000000000000$	est for overall effect:	Z = 8.01	(P < 0	.00001)						
$\frac{1}{3} = \frac{1}{2} + \frac{1}$.10.3 GC+TGP VS GO	:									
$\frac{1}{3}$ $\frac{1}{1} = \frac{1}{1} + \frac{1}$	nu Y 2009	13.4	7.3	35	22.5	11.6	30	8.8%	-0.94 [-1.46, -0.43]	▲	
$\frac{1}{2} = \frac{1}{2} = \frac{1}$	Subtotal (95% CI)	ulia a la la		35			30	8.8%	-0.94 [-1.46, -0.43]	•	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	selenineneme Mint an										
303 100 % - 2.17 [3.43, -2.05] 303 100 % - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.43, -2.05] - 2.17 [3.46 (P < 0.00001); P = 90.6%	<th>est for overall effect:</th> <th>Z = 3.59</th> <th>(P = 0</th> <th>.0003)</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	est for overall effect:	Z = 3.59	(P = 0	.0003)						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	est for overall effect:	Z = 3.59	(P = 0	.0003)			356	100.0%	2771348 2061	•	
$3 \\ \hline \\ \textbf{Std. Mean Difference} \\ \textbf{Std. Mean Difference} \\ \textbf{tudy or Subgroup} \\ \hline \textbf{Mean} \textbf{SD} \textbf{Total} \textbf{Mean} \textbf{Mean} \textbf{SD} \textbf{Total} \textbf{Mean} \textbf{Mean} \textbf{SD} \textbf{Total} \textbf{Mean} M$	Fest for overall effect:	Z = 3.59	(P = 0	.0003) 365	f= 11 (P≼∩í	356	100.0%	-2.77 [-3.48, -2.06]	•	
$ \frac{1}{3} $ $ \frac{1}{3} $ $ \frac{1}{3} 1$	ieterogeneity: retra; ieterogeneity: Tau ² = ieterogeneity: Tau ² =	Z = 3.59 1.42; Cl 7 = 7.64	(P = 0 hi² = 13 (P < 0	.0003) 365 80.96, c	if= 11 (i	P < 0.(356)0001);	100.0 % ² = 92%	-2.77 [-3.48, -2.06]	◆ -10 -5 0 5 10	
Std. Mean Difference Std. Mean	est for overall effect: otal (95% CI) leterogeneity: Tau ² = est for overall effect: est for subaroup diff	Z = 3.59 1.42; Cl Z = 7.64 erences	(P = 0 hi ² = 13 (P < 0 : Chi ² =	.0003) 365 0.96, c .00001 : 21.37	lf=11 ()) . df=2 (P < 0.((P < 0.	356)0001); 0001).	100.0% ² = 92% ² = 90.6%	-2.77 [-3.48, -2.06]	+ -10 -5 0 5 10 experimental control	
Experimental Control Std. Mean Difference Std. Mean Difference Std. Mean Difference Std. Mean Difference V, Random, 95% Cl tudy or Subgroup Mean SD Total Mean SD Total Weight N, Random, 95% Cl N, Random, 95% Cl tai H 2017 8.79 0.63 30 9.23 0.78 30 10.4% -0.61 [-1.13, -0.09] N, Random, 95% Cl N, Rando	Test for overall effect: otal (95% Cl) Heterogeneity: Tau ² = est for overall effect: est for subαroup diff	Z = 3.59 1.42; Cl Z = 7.64 erences	(P = 0 hi ² = 13 (P < 0 : Chi ² =	.0003) 365 0.96, c .00001 : 21.37	if=11 ()) . df=2 (P < 0.((P < 0.	356)0001); 0001).	100.0% ² = 92% ² = 90.6%	-2.77 [-3.48, -2.06]	-10 -5 0 5 10 experimental control	
tudy or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI cai H 2017 8.79 0.63 30 9.23 0.78 30 10.4% -0.61 [-1.13, -0.09]	est for overall effect: otal (95% Cl) leterogeneity: Tau ² = est for overall effect: est for subαroup diff	Z = 3.59 1.42; Cl Z = 7.64 erences	(P = 0 hi ² = 13 (P < 0 : Chi ² =	.0003) 365 80.96, c .00001 : 21.37	if=11 () .df=2 (P < 0.((P < 0.	356)0001); 0001).	100.0% ² = 92% ² = 90.6%	-2.77 [-3.48, -2.06]	← -10 -5 0 5 10 experimental control	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	iest for overall effect: otal (95% Cl) leterogeneity: Tau ² = est for overall effect: est for subαroup diff	Z = 3.59 1.42; Cl Z = 7.64 erences Expe	(P = 0 hi ² = 13 (P < 0 : Chi ² =	.0003) 365 0.96, c .00001 : 21.37 tal	lf = 11 ()) . df = 2 (C	P < 0.((P < 0. ontrol	356)0001); 0001).	100.0% ² = 92% ² = 90.6%	-2.77 [-3.48, -2.06]	+ -10 -5 0 5 10 experimental control Std. Mean Difference	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	iest for overall effect: otal (95% Cl) leterogeneity: Tau ² = est for overall effect: est for subaroup diff B tudy or Subgroup	Z = 3.59 1.42; Cl Z = 7.64 erences Expe <u>Mean</u>	(P = 0 hi ² = 13 (P < 0 : Chi ² = eriment SD	.0003) 365 0.96, c .00001 : 21.37 tal Total	if = 11 (i) . df = 2 (C <u>Mean</u>	P < 0.((P < 0. ontrol SD	356)0001); 0001). 	100.0% ² = 92% ² = 90.6% <u>Weight</u>	-2.77 [-3.48, -2.06] , Std. Mean Difference <u>IV, Random, 95% CI</u>		
eng P 2017 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 $[-11.43, -7.52]$ iX 2020 2.21 1.12 33 19.2 2.21 33 9.9% -9.58 $[-11.34, -7.83]$ in G 2016 1.64 0.83 26 9.7 0.72 25 9.6% -10.20 $[-12.33, -8.07]$ eng H 2018 1.4 1.3 20 18 2.1 20 9.5% -9.32 $[-11.55, -7.08]$ iang S 2020 1.85 0.46 35 9.06 1.37 35 10.2% -6.98 $[-8.26, -5.70]$ u F 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 $[-11.43, -7.52]$ u Y 2020 6.52 0.96 36 14.25 3.46 36 10.4% -3.01 $[-3.70, -2.33]$ u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 $[-8.28, -5.53]$ otal (95% CI)285281 100.0% -6.86 $[-9.15, -4.56]$ -20 -10 0 10 20 ext for overall effect: $Z = 5.86$ (P < 0.00001)	Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diff B <u> Hudy or Subgroup</u> Sai H 2017	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79	(P = 0 hi ² = 13 (P < 0 : Chi ² = eriment <u>SD</u> 0.63	.0003) 365 0.96, c .00001 21.37 tal <u>Total</u> 30	if = 11 (i) . df = 2 (C <u>Mean</u> 9.23	P < 0.((P < 0.) ontrol <u>SD</u> 0.78	356)0001); 0001). <u>Total</u> 30	100.0% ² = 92% ² = 90.6% <u>Weight</u> 10.4%	-2.77 [-3.48, -2.06] , Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09]	+ -10 -5 0 5 10 experimental control Std. Mean Difference IV. Random, 95% Cl +	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	rest for overall effect: rotal (95% Cl) Heterogeneity: Tau ² = rest for overall effect: rest for suboroup diff B <u> Hudty or Subgroup</u> het J 2017 het J 2013	Z = 3.59 1.42; Cl Z = 7.64 erences Expe <u>Mean</u> 8.79 9.8	(P = 0 hi ² = 13 (P < 0 : Chi ² = criment <u>SD</u> 0.63 1.02	.0003) 365 0.96, c .00001 21.37 tal <u>Total</u> 30 21	if = 11 (i) . df = 2 (<u>Mean</u> 9.23 17.6	P < 0.0 (P < 0. ontrol <u>SD</u> 0.78 2.61	356 00001); 0001). <u>Total</u> 30 20	100.0 % ² = 92% ² = 90.6% <u>Weight</u> 10.4% 10.3%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82]	+ -10 -5 0 5 10 experimental control Std. Mean Difference IV. Random, 95% Cl	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	rest for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diff B Hudy or Subgroup Nen J 2013 Ten P 2017 Ten P 2017	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42	(P = 0 hi ² = 13 (P < 0 : Chi ² = 0.63 1.02 1.24	.0003) 365 80.96, c .00001 21.37 tal <u>Total</u> 30 21 27	lf = 11 ()) . df = 2 (<u>Mean</u> 9.23 17.6 18.1	P < 0.0 (P < 0. ontrol <u>SD</u> 0.78 2.61 2.13	356 00001); 0001). <u>Total</u> 30 20 26	100.0% ² = 92% ² = 90.6% Weight 10.4% 10.3% 9.8%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52]	-10 -5 0 5 10 experimental control Std. Mean Difference IV, Random, 95% Cl	
teng H 2018 1.4 1.3 20 18 2.1 20 9.5% -9.32 [-11.55, -7.08] tiang S 2020 1.85 0.46 35 9.06 1.37 35 10.2% -6.98 [-8.26, -5.70] u F 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [-11.43, -7.52] u Y 2020 6.52 0.96 36 14.25 3.46 36 10.4% -3.01 [-3.70, -2.33] u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 [-8.28, -5.53] otal (95% Cl) 285 281 100.0% -6.86 [-9.15, -4.56] -20 -10 0 10 20 est for overall effect: $Z = 5.86$ (P < 0.00001) P < 0.00001) P = 97% -20 -10 0 10 20 urg x 8 URE 8 S S 20.00001 20 20 20 -10 10 20	Fest for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for subaroup diff B Study or Subgroup Nen J 2013 Hen J 2013 Hen J 2013 Hen J 2017 JX 2020	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21	(P = 0 (P < 0) : Chi ² = 0.63 1.02 1.24 1.12	.0003) 365 80.96, c .00001 : 21.37 tal <u>Total</u> 30 21 27 33	lf = 11 ()) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2	P < 0.0 (P < 0. ontrol <u>SD</u> 0.78 2.61 2.13 2.21	356)0001); 0001). <u>Total</u> 30 20 26 33	100.0% ² = 92% ² = 90.6% Weight 10.4% 10.3% 9.8% 9.9%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.53]	-10 -5 0 5 10 experimental control Std. Mean Difference IV, Random, 95% Cl	
liang S 2020 1.85 0.46 35 9.06 1.37 35 10.2% -6.98 [-8.26, -5.70] u F 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [-11.43, -7.52] u Y 2020 6.52 0.96 36 14.25 3.46 36 10.4% -3.01 [-3.70, -2.33] u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 [-8.28, -5.53] otal (95% Cl) 285 281 100.0% leterogeneity: Tau ² = 13.05; Chi ² = 355.69, df = 9 (P < 0.00001); P = 97% est for overall effect: Z = 5.86 (P < 0.00001) URE 8	Fest for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for suboroup diff B Hudy or Subgroup Sai H 2017 Shen J 2013 Feng P 2017 JX 2020 Jn G 2016	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21 1.64	(P = 0 (P < 0 (P < 0 : Chi ² = 0.63 1.02 1.24 1.12 0.83	.0003) 365 .0.96, c .00001 : 21.37 tal <u>Total</u> 30 21 27 33 26	if = 11 (i) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7	P < 0.0 (P < 0. ontrol <u>SD</u> 0.78 2.61 2.13 2.21 0.72	356)0001); 0001). <u>Total</u> 30 20 26 33 25	100.0% ² = 92% ² = 90.6% Weight 10.4% 10.3% 9.8% 9.6%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.53] -10.20 [-12.33, -8.07]	-10 -5 0 5 10 experimental control Std. Mean Difference IV, Random, 95% Cl	
u F 2015 1.42 1.24 27 18.1 2.13 26 9.8% -9.48 [-11.43, -7.52] u Y 2020 6.52 0.96 36 14.25 3.46 36 10.4% -3.01 [-3.70, -2.33] u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 [-8.28, -5.53] otal (95% Cl) 285 281 100.0% -6.86 [-9.15, -4.56] -20 -10 0 10 20 est for overall effect: Z = 5.86 (P < 0.00001)	Fest for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for suboroup diff B Study or Subgroup Sai H 2017 Shen J 2013 Feng P 2017 J X 2020 J in G 2016 Peng H 2018	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21 1.64 1.64	(P = 0 (P < 0 (P < 0 : Chi ² = 0.63 1.02 1.24 1.12 0.83 1.3	.0003) 365 .0.96, c .00001 : 21.37 tal <u>Total</u> 30 21 37 33 26 20	if = 11 ()) . df = 2 () <u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18	P < 0.((P < 0. (P < 0. 0.78 2.61 2.13 2.21 0.72 2.1	356 00001); 00001). <u>Total</u> 30 20 26 333 25 20	100.0% ² = 92% ² = 90.6% (Weight 10.4% 10.3% 9.8% 9.8% 9.6%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV. Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.83] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08]	-10 -5 0 5 10 experimental control Std. Mean Difference IV. Random, 95% Cl	
u Y 2020 6.52 0.96 36 14.25 3.46 36 10.4% -3.01 [-3.70, -2.33] u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 [-8.28, -5.53] otal (95% Cl) 285 281 100.0% -6.86 [-9.15, -4.56] -20 -10 0 10 20 eterogeneity: Tau ² = 13.05; Chi ² = 355.69, df = 9 (P < 0.00001); I ² = 97% -20 -10 0 10 20 est for overall effect: Z = 5.86 (P < 0.00001)	Fest for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Test for subaroup diff B Study or Subgroup Cai H 2017 Chen J 2013 Teng P 2017 Li X 2020 Lin G 2016 Peng H 2018 Gang S 2020	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21 1.64 1.4 1.85	(P = 0 hi ² = 13 (P < 0 : Chi ² = 0.63 1.02 1.24 1.12 0.83 1.3 0.46	.0003) 365 0.96, c .00001 21.37 tal <u>Total</u> 30 21 27 33 26 20 35	if = 11 (i) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06	P < 0.0 (P < 0. 0.78 2.61 2.13 2.21 0.72 2.1 1.37	356 00001); 00001). <u>Total</u> 30 20 26 33 25 20 35	100.0% ² = 92% ² = 90.6% Weight 10.4% 10.3% 9.8% 9.6% 9.5% 10.2%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.83] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70]	Std. Mean Difference N. Random, 95% Cl	
u H 2019 1.84 0.47 30 9.05 1.38 30 10.1% -6.90 [-8.28, -5.53] otal (95% Cl) 285 281 100.0% -6.86 [-9.15, -4.56] leterogeneity: Tau² = 13.05; Chi² = 355.69, df = 9 (P < 0.00001); I² = 97%	First for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Test for suboroup diff B Study or Subgroup Sai H 2017 Shen J 2013 Teng P 2017 Jin G 2016 Peng H 2018 Gang S 2020 (u F 2015	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21 1.64 1.42 1.42 1.42	(P = 0 hi ² = 13 (P < 0 : Chi ² = 0.63 1.02 1.24 1.12 0.83 1.3 0.46 1.24	.0003) 365 0.96, c .00001 21.37 tal <u>Total</u> 30 21 27 33 26 20 35 27	if = 11 (i) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1	P < 0.0 (P < 0. 5D 0.78 2.61 2.13 0.72 2.11 1.37 2.13	356 00001); 0001). <u>Total</u> 30 20 26 33 25 25 25 25 25 25 26	100.0% ² = 92% ² = 90.6% Weight 10.4% 10.3% 9.8% 9.6% 9.5% 10.2% 9.8%	-2.77 [-3.48, -2.06] Std. Mean Difference IV, Random, 95% CI -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.83] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52]	Std. Mean Difference V. Random, 95% Cl	
otal (95% CI) 285 281 100.0% -6.86 [-9.15, -4.56] leterogeneity: Tau ² = 13.05; Chi ² = 355.69, df = 9 (P < 0.00001); I ² = 97% -20 -10 0 10 20 est for overall effect: Z = 5.86 (P < 0.00001)	Fiest for overall effect: Fiest for overall effect: Fiest for overall effect: Fiest for overall effect: Fiest for subgroup diff B Findy or Subgroup Cai H 2017 Chen J 2013 Fieng P 2017 Chen J 2013 Fieng P 2017 Chen J 2013 Fieng P 2017 Chen J 2013 Fieng P 2017 Chen J 2013 Chen J 2013 Chen J 2013 Chen J 2015 Chen J 2020 Chen J 2020 Che	Z = 3.59 1.42; Cl Z = 7.64 erences Expe <u>Mean</u> 8.79 9.8 1.42 2.21 1.64 1.42 1.42 1.42 1.42 6.52	(P = 0 hi [#] = 13 (P < 0 : Chi [#] = Chi [#] = 0.63 1.02 1.24 1.12 0.83 1.3 0.46 1.24 1.22 0.83	365 0.96, c .00001 21.37 tal Total 30 21 27 33 26 20 35 27 36	ff = 11 (i) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1 14.25	P < 0.0 (P < 0. 0.78 2.61 2.13 2.21 1.37 2.13 3.46	356 00001); 0001). 0001). 20 20 26 33 25 20 26 33 25 20 35 20 35 20 35 36 36	100.0% ² = 92% ² = 90.6% (10.4% 10.3% 9.8% 9.8% 9.6% 9.6% 10.2% 9.8% 10.2% 9.8% 10.4%	-2.77 [-3.48, -2.06] Std. Mean Difference IV, Random, 95% CI -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.83] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52] -3.01 [-3.70, -2.33]	-10 -5 0 5 10 experimental control Std. Mean Difference IV, Random, 95% Cl	
Iderogeneity: Tau² = 13.05; Chi² = 355.69, df = 9 (P < 0.00001); I² = 97%	First for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for suboroup diff B Study or Subgroup Sai H 2017 Chen J 2013 Feng P 2017 Li X 2020 Lin G 2016 Peng H 2018 Gang S 2020 Gu F 2015 Gu Y 2020 Yu H 2019	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21 1.64 1.42 1.65 1.42 6.52 1.84	(P = 0 hi ² = 13 (P < 0 : Chi ² = 0.63 1.02 1.24 1.12 0.83 1.3 0.46 1.24 0.96 0.47	00003) 365 00.96, c 00001 21.37 tal Total 30 21 27 33 26 20 35 27 36 30 30 30 30 30 31 32 32 33 30 30 30 30 30 30 30 30 30	ff = 11 (i) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1 14.25 9.05	P < 0.(P < 0. 0.78 2.61 2.13 0.72 2.1 1.37 2.13 3.46 1.38	356 00001); 00001). 00001). 30 20 20 20 20 20 20 35 20 35 20 35 26 36 30	100.0% ² = 92% ² = 90.6% (10.4% 10.3% 9.8% 9.8% 9.5% 10.2% 9.8% 10.4% 10.4% 10.1%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.53] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52] -3.01 [-3.70, -2.33] -6.90 [-8.28, -5.53]	Std. Mean Difference N. Random, 95% CI	
est for overall effect: Z = 5.86 (P < 0.00001) -20 -10 -20 -20 -10 -20 -20 -20 -20 -20 -20 -20 -20 -20 -2	First for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for subaroup diff B Study or Subgroup Cai H 2017 Chen J 2013 Seng P 2017 JX 2020 Jin G 2016 Seng H 2018 Gang S 2020 Gur F 2015 Gur S 2020 Gur F 2015 Gur Y 2020 Gur H 2019 Sotal (95% CI)	Z = 3.59 1.42; Cl Z = 7.64 erences <u>Expe</u> <u>Mean</u> 8.79 9.8 1.42 2.21 1.64 1.42 1.42 1.42 6.52 1.84	(P = 0 hi ² = 13 (P < 0 : Chi ² = SD 0.63 1.02 1.24 1.22 0.83 1.3 0.46 1.24 0.96 0.47	.0003) 365 10.96, c .00001 : 21.37 tal Total 30 21 37 33 26 20 35 27 36 30 285	ff = 11 (() . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1 14.25 9.05	P < 0.(P < 0. (P < 0. 0.78 2.61 2.13 2.21 0.72 2.13 3.46 1.38	356)0001); 0001). 0001). 100010. 100000. 100000000. 100000	100.0% ² = 92% ² = 90.6% (10.4%) 10.4% 9.8% 9.5% 10.2% 9.8% 10.4% 10.4% 10.1% 100.0%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.83] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52] -3.01 [-3.70, -2.33] -6.90 [-8.28, -5.53] -6.86 [-9.15, -4.56]	Std. Mean Difference V, Random, 95% Cl	
URE 8	Fest for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Fest for subaroup diff B <u>Study or Subgroup</u> Cai H 2017 Chen J 2013 Eeng P 2017 Li X 2020 Lin G 2016 Peng H 2018 Gang S 2020 Cu F 2015 Cu Y 2020 Yu H 2019 Tau ² = Tau ² =	Z = 3.59 1.42; Cl Z = 7.64 erences Expe Mean 8.79 9.8 1.42 2.21 1.64 1.42 6.52 1.84 1.3.05; ((P = 0) $hi^2 = 13$ (P < 0) $: Chi^2 =$ $I = 10^{-1}$ $: Chi^2 =$ $I = 10^{-1}$ $I = 10^{-1}$ I =	.0003) 365 10.96, c .00001 21.37 tal Total 30 21 27 33 26 20 35 27 36 30 285 305.69, c	ff = 11 (()) . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1 14.25 9.05	P < 0.(P < 0. (P < 0. 0.78 2.61 2.13 2.21 0.72 2.1 1.37 2.13 3.46 1.38 (P < 0.	356)0001); 0001). <u>Total</u> 30 20 20 33 25 20 35 26 36 30 281 00001)	100.0% ² = 92% ² = 90.6% ² = 90.6% 10.4% 9.8% 9.6% 9.8% 10.2% 9.8% 10.4% 10.4% 10.1% 100.0% ; ² = 97%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52] -3.01 [-3.70, -2.33] -6.90 [-8.28, -5.53] -6.86 [-9.15, -4.56]	Std. Mean Difference N, Random, 95% Cl + + + + + + + + + + + + +	
URE 8	Fest for overall effect: Fotal (95% CI) Heterogeneity: Tau ² = Fest for overall effect: Test for suboroup diff B Study or Subgroup Cai H 2017 Chen J 2013 Feng P 2017 Cai H 2017 Chen J 2013 Cai H 2017 Cai H 2017 Cai H 2018 Cang B 2020 Cui F 2015 Cui F 2015 Cui F 2015 Cui F 2019 Cui H 2019 Cotal (95% CI) Heterogeneity: Tau ² = Set for overall effect:	Z = 3.59 1.42; Cl Z = 7.64 erences Expe Mean 8.79 9.8 1.42 2.21 1.64 1.85 1.42 6.52 1.84 :13.05; (Z = 5.86	(P = 0) $hi^2 = 13$ (P < 0) $: Chi^2 =$ 1.24 1.22 1.24 0.83 1.3 0.46 1.24 0.96 0.47 $Chi^2 = 3$ i (P < 0)	.0003) 365 10.96, c .00001 21.37 tal Total 30 21 27 326 20 35 27 36 30 285 355.69 .00001	ff = 11 (()) . df = 2 () 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1 14.25 9.05 , df = 9 ()	P < 0.(P < 0. 0.78 2.61 2.13 2.21 0.72 2.1 1.37 2.13 3.46 1.38 (P < 0.)	356)0001); 0001). 0001). 30 20 26 33 325 20 35 26 36 36 30 30 281 000001)	100.0% ² = 92% ² = 90.6% ² = 90.6% 10.4% 9.8% 9.8% 9.6% 9.5% 10.2% 9.8% 10.4% 10.4% 10.1% 100.0% ; ² = 97%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>IV, Random, 95% CI</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.83] -10.20 [-12.33, -8.07] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52] -3.01 [-3.70, -2.33] -6.90 [-8.28, -5.53] -6.86 [-9.15, -4.56]	Std. Mean Difference N, Random, 95% Cl -10 -20 -20 -10 -10 -5 0 5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 10 -5 -5 -5 -5 -5 -5 -5 -5 -5 -5	
	est for overall effect: otal (95% CI) leterogeneity: Tau ² = est for overall effect: est for suboroup diff 3 tudy or Subgroup is H 2017 then J 2013 eng P 2017 ix 2020 in G 2016 eng H 2018 iang S 2020 u F 2015 u Y 2020 u H 2019 otal (95% CI) leterogeneity: Tau ² = est for overall effect:	Z = 3.59 1.42; Cl Z = 7.64 erences Expe Mean 8.79 9.8 1.42 2.21 1.64 1.42 1.62 1.84 1.85 1.42 6.52 1.84 	(P = 0) $hi^2 = 13$ (P < 0) $: Chi^2 =$ 1.24 1.12 1.24 1.24 1.24 0.83 0.83 0.83 0.46 1.24 0.96 0.47 $Chi^2 = 3$ (P < 0)	.0003) 365 10.96, c .00001 21.37 tal 30 21 27 33 26 20 35 27 36 30 285 355.69 .00001	ff = 11 (() . df = 2 (<u>Mean</u> 9.23 17.6 18.1 19.2 9.7 18 9.06 18.1 14.25 9.05 , df = 9 ()	P < 0.(P < 0. 0.78 2.61 2.13 2.21 0.72 2.1 1.37 2.13 3.46 1.38 (P < 0.	356 00001); 0001). 0001). 30 20 20 20 20 25 20 35 26 36 36 30 281 200001)	100.0% ² = 92% ² = 90.6% 10.4% 10.4% 9.8% 9.6% 9.5% 10.2% 9.8% 10.4% 10.4% 10.1% 100.0% ; ² = 97%	-2.77 [-3.48, -2.06] Std. Mean Difference <u>W, Random, 95% Cl</u> -0.61 [-1.13, -0.09] -3.90 [-4.98, -2.82] -9.48 [-11.43, -7.52] -9.58 [-11.34, -7.52] -9.32 [-11.55, -7.08] -6.98 [-8.26, -5.70] -9.48 [-11.43, -7.52] -3.01 [-3.70, -2.33] -6.90 [-8.28, -5.53] -6.86 [-9.15, -4.56]	Std. Mean Difference N. Random, 95% CI	

3.4.9 24 h urine protein

Ten studies reported 24 h urine protein as the outcome, including 294 patients overall in the experimental group and 288 patients overall in the control group. All the ten studies (Chen, 2013; Sun, 2013; Xu, 2015; Lin and Liu, 2016; Cai et al., 2017; Feng et al., 2017; Peng, 2018; Li and Zheng, 2020; Xiang, 2020; Xu, 2020) used TGP in combination with GC and CTX. A fixed-effects model was applied for analysis because of low heterogeneity

(I² = 39%, *p* = 0.10). Subgroup analysis showed that the 24 h urine protein in the experimental group was significantly lower than that in the control group (SMD = -0.73, 95% Cl = [-0.90, -0.57], *p* < 0.001). The difference was statistically significant (Figure 7C).

3.4.10 Average daily dosage of GC

Twelve studies reported the average daily dosage of GC as the outcome, including 365 patients overall in the experimental

group and 356 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. Ten studies (Chen, 2013; Xu, 2015; Lin and Liu, 2016; Cai et al., 2017; Feng et al., 2017; Peng, 2018; Yu et al., 2019; Li and Zheng, 2020; Xiang, 2020; Xu, 2020) used TGP in combination with GC and CTX. One study (Li Z. et al., 2018) used TGP in combination with GC and TAC. One study (Zhu and Wei, 2009) used TGP in combination with GC and TAC. One study (Zhu and Wei, 2009) used TGP in combination with GC. A random-effects model was applied for analysis because of the existence of heterogeneity ($I^2 = 92\%$, p < 0.001). Subgroup analysis showed that the average daily dosage of GC in the experimental group was lower than that of the control group (SMD = -3.04, 95% Cl = [-3.83, -2.24], p < 0.001; SMD = -0.94, 95% Cl = [-1.46, -0.43], p < 0.001). The difference was statistically significant (Figure 8A).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. It was found that three studies (Zhu and Wei, 2009; Cai et al., 2017; Li Z. et al., 2018) had a significant impact on the result. The heterogeneity was reduced after excluding the three articles (I² = 28%, p = 0.20). We merged the data of other studies to analyze (SMD = -3.30, 95% Cl = [-3.62, -2.97], p < 0.001). One study (Cai et al., 2017) had a shorter average course of disease, and the other two studies (Zhu and Wei, 2009; Li Z. et al., 2018) were combined with different drugs, which may be the main reason for heterogeneity. (Supplementary Figure S5).

3.4.11 Cumulative dosage of CTX

Ten studies reported the cumulative dosage of CTX, including 285 patients overall in the experimental group and 281 patients overall in the control group. All the ten studies (Chen, 2013; Xu, 2015; Lin and Liu, 2016; Cai et al., 2017; Feng et al., 2017; Peng, 2018; Yu et al., 2019; Li and Zheng, 2020; Xiang, 2020; Xu, 2020) used TGP in combination with GC and CTX. A random-effects model was applied for analysis because of the existence of heterogeneity ($I^2 = 97\%$, p < 0.001). Subgroup analysis showed that the cumulative dosage of CTX in the experimental group was significantly lower than that of the control group (SMD = -6.86, 95% Cl = [-9.15, -4.56], p < 0.001). The difference was statistically significant (Figure 8B).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. It was found that five studies (Chen, 2013; Cai et al., 2017; Yu et al., 2019; Xiang, 2020; Xu, 2020) had a significant impact on the result. The heterogeneity was reduced after excluding the five studies (I² = 0%, p = 0.98). We merged the data of other studies to analyze (SMD = -9.60, 95% Cl = [-10.49, -8.72], p < 0.001). The large differences in the mean age and treatment duration of the patients in the five studies compared with the other studies may account for the heterogeneity (Supplementary Figure S6).

3.4.12 Recurrence rate

Ten studies reported the recurrence rate, including 361 patients overall in the experimental group and 359 patients overall in the control group. Subgroup analysis was performed according to different treatment drugs. Six studies (Lin and Liu, 2016; Feng et al., 2017; Peng, 2018; Li and Zheng, 2020; Wu et al., 2020; Xu, 2020) used TGP in combination with GC and CTX. One study (Li Z. et al., 2018) used TGP in combination with GC and TAC. Three studies (Li, 2013; Wang et al., 2013; Liu, 2016) used TGP in combination with GC. A fixed-effects model was applied for analysis because of low heterogeneity ($I^2 = 0\%$, p = 0.74). Subgroup analysis showed that the recurrence rate of the experimental group was lower than that of the control group (RR = 0.32, 95% Cl = [0.19,0.53], *p* < 0.001; RR = 0.43, 95% Cl = [0.18, 1.02], *p* < 0.05; RR = 0.14, 95% Cl = [0.06, 0.32], p < 0.001). The difference was statistically significant (Figure 9).

3.5 Safety outcomes

3.5.1 Incidence of adverse reactions

Eighteen studies reported the incidence of adverse reactions, including 631 patients overall in the experimental group and 626 patients overall in the control group. Subgroup analysis was performed according to the different treatment drugs. Eleven studies (Chen, 2013; Xu, 2015; Lin and Liu, 2016; Yang, 2016; Cai et al., 2017; Feng et al., 2017; Peng, 2018; Yu et al., 2019; Li and Zheng, 2020; Wu et al., 2020; Xu, 2020) used TGP in combination with GC and CTX. Two studies (Xue and Lyu, 2019; Zhao et al., 2020) used TGP in combination with GC and HCQ. One study (Li Z. et al., 2018) used TGP in combination with GC and TAC. Four studies (Wang et al., 2013; Wang and Wang, 2015; Liu, 2016; Yang and Li, 2019) used TGP in combination with GC. A random-effects model was applied for analysis because of the existence of heterogeneity ($I^2 = 69\%$, p < 0.001). Subgroup analysis showed that the incidence of adverse reactions in TGP combined with GC and CTX treatment was lower than that in the control group (RR = 0.37, 95% Cl = [0.21, 0.64], p <0.001), and the difference was statistically significant. The remaining three groups had no significant advantage over the control group in the incidence of adverse reactions (RR = 0.60, 95% Cl = [0.15, 2.44], *p* = 0.48; RR = 1.40, 95% Cl = [0.48, 4.08], *p* = 0.54; RR = 0.54, 95% Cl = [0.18, 1.61], *p* = 0.27) (Figure 10).

Sensitivity analysis was performed to explore the source of heterogeneity by excluding articles sequentially and reading the full text. Four studies (Wang and Wang, 2015; Yang, 2016; Yang and Li, 2019; Wu et al., 2020) were found to have a significant impact on the result. The heterogeneity was reduced after excluding the four studies (I² = 3%, p = 0.41). We merged the data of other studies to analyze (SMD = 0.34, 95% Cl = [0.25, 0.46], p < 0.001). The inconsistency in the evaluation criteria for

	Experim	ental	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
2.1.1 GC+CTX+TGP V	S GC+CTX						
Feng P 2017	2	27	8	26	7.2%	0.24 [0.06, 1.03]	
Li X 2020	2	33	8	33	7.0%	0.25 [0.06, 1.09]	
Lin G 2016	2	26	8	25	7.2%	0.24 [0.06, 1.02]	
Peng H 2018	1	20	6	20	3.7%	0.17 [0.02, 1.26]	
Wu X 2020	7	37	15	37	25.3%	0.47 [0.22, 1.01]	
Xu Y 2020	2	36	8	36	6.9%	0.25 [0.06, 1.10]	
Subtotal (95% CI)		179		177	57.2%	0.32 [0.19, 0.53]	•
Total events	16		53				
Heterogeneity: Tau ² =	= 0.00; Chi ²	= 1.88,	df = 5 (P	= 0.87); I² = 0%		
Test for overall effect	Z = 4.37 (F	° < 0.00	101)				
2.1.2 GC+Tac+TGP V	S GC+Tac						
Li Z 2018	6	45	14	45	20.3%	0.43 [0.18, 1.02]	
Subtotal (95% CI)		45		45	20.3%	0.43 [0.18, 1.02]	◆
Total events	6		14				
Heterogeneity: Not ap	oplicable						
Test for overall effect	Z = 1.93 (F	P = 0.05	i)				
2.1.3 GC+TGP VS GC							
Li Y 2013	2	47	14	47	7.4%	0.14 (0.03, 0.59)	
Liu W 2016	2	43	15	43	7.6%	0.13 [0.03, 0.55]	
Wang Z 2013	2	47	14	47	7.4%	0.14 [0.03, 0.59]	
Subtotal (95% CI)		137		137	22.4%	0.14 [0.06, 0.32]	◆
Total events	6		43				
Heterogeneity: Tau ² =	= 0.00; Chi ²	= 0.01,	df = 2 (P	= 1.00); I ² = 0%		
Test for overall effect	Z = 4.70 (F	° < 0.00	1001)				
Total (95% CI)		361		359	100.0%	0.28 [0.19, 0.41]	•
Total events	28		110				
Heterogeneity: Tau ² =	= 0.00; Chi ²	= 6.04	df = 9 (P	= 0.74); ² = 0%		
Test for overall effect	Z = 6.40 (F	< 0.00	001)				0.002 0.1 1 10 500
Test for subaroup dif	ferences: C	hi² = 3.	93. df = 2	? (P = 0	.14), I² = 4	19.2%	experimental control
GURE 9							
prest plot of recurrence	ce rate.						

the occurrence of adverse reactions among the four studies may be the main reason for heterogeneity (Supplementary Figure S7).

3.6 Publication bias

We used RevMan 5.3 software to draw a funnel plot for the incidence of adverse reactions to analyze publication bias. The results show that the two sides of the funnel plot are asymmetrical, indicating some publication bias in the included literature, which may be related to the evaluation criteria for the incidence of adverse reactions, the small sample size of individual studies, and unpublished negative results (Figure 11).

3.7 GRADE assessment

According to the GRADE methodology, the SLEDAI score, the incidence of adverse reactions, and the recurrence rate of TGP combined with different drugs for SLE were evaluated with evidence levels of "medium" and "low." The results of the GRADE evaluation are shown in Table 2.

4 Discussion

SLE is a chronic autoimmune disease that requires clinical monitoring of multiple indicators to assess disease activity to guide clinical treatment. Among the SLE disease activity assessment tools, SLEDAI is widely adopted by clinicians because of its relatively easy and time-consuming assessment process (Chinese Rheumatology Association, 2020). ESR is a non-specific inflammatory index, but it is a valid indicator for the disease activity assessment in patients with non-infectious SLE (Dima et al., 2016). Low complement is an important serological manifestation of SLE and decreased C3 and C4 can predict SLE flares (Durcan and Petri, 2020). Urine protein reflects renal pathology, and studies have found a positive correlation between 24 h urine protein and SLE disease activity (Li M. et al., 2018). In this study, we evaluated the efficacy and safety

	Experime	ntal	Contro	ol		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl			
2.2.1 GC+CTX+TGP V	S GC+CTX									
Cai H 2017	2	30	7	30	4.2%	0.29 [0.06, 1.26]				
Chen J 2013	2	47	11	47	4.3%	0.18 [0.04, 0.78]				
Feng P 2017	4	27	14	26	6.2%	0.28 [0.10, 0.73]				
Li X 2020	3	33	18	33	5.6%	0.17 [0.05, 0.51]				
Lin G 2016	5	26	12	25	6.6%	0.40 [0.16, 0.97]				
Peng H 2018	2	20	9	20	4.5%	0.22 [0.05, 0.90]				
Wu X 2020	6	37	5	37	5.7%	1.20 (0.40, 3.59)	_ -			
Xu F 2015	4	27	14	26	6.2%	0.28 (0.10, 0.73)	_ - _			
Xu Y 2020	3	36	11	36	5.3%	0.27 (0.08, 0.90)	_ _			
Yang M 2016	20	26	20	24	9.2%	0.92 (0.20, 0.00)	+			
Vu ⊔ 2010	20	20	17	20	7 6%	0.32 [0.70, 1.22]				
Subtotal (05% CI)	0	330	17	334	65 5%	0.37 [0.24, 0.32]	•			
Total events	50	333	100	554	03.370	0.57 [0.2 1, 0.04]	•			
Total events	0.50.01.2	10.00	130	(D	000041-17	- 700				
Test for overall effect:	Z = 3.52 (P	= 42.50 = 0.00	0, af = 101 04)	(P < U.	00001); F	-= / 0%				
2.2.2.60+00+100+	IS GC+UCO									
2.2.2 0C+HCQ+10P V	SOCTICO	~~	~	~~	0.00	0.50 10.05 5.00				
Xue Y2019	1	30	2	30	2.3%	0.50 [0.05, 5.22]				
Zhao L2020	2	53	3	53	3.5%	0.67 [0.12, 3.83]				
Subtotal (95% CI)		83		83	5.8%	0.60 [0.15, 2.44]				
Total events	3		5							
Heterogeneity: Tau ² =	0.00; Chi ² :	= 0.04,	df = 1 (P :	= 0.85)); I² = 0%					
Test for overall effect:	Z=0.71 (P	= 0.48)							
2.2.3 GC+Tac+TGP V	S GC+Tac									
Li Z 2018	7	45	5	45	5.8%	1.40 [0.48, 4.08]				
Subtotal (95% CI)		45		45	5.8%	1.40 [0.48, 4.08]	•			
Total events	7		5							
Heterogeneity: Not ap	plicable									
Test for overall effect:	Z=0.62 (P	= 0.54)							
2.2.4 GC+TGP VS GC										
Liu W 2016	2	43	12	43	4 4 %	0.17 (0.04 / 0.70)				
Wang D 2015	11	21	.2	21	7 6%	1 38 10 70 2 721	- -			
Mang 7 2013	2	47	11	47	1 3%	0.18 [0.04 0.79]				
Vang 2 2010 Vang X 2010	2 0	52		52	6.70	1 13 10 / 7 3 601	_ _			
Subtotal (05% CI)	5	164	0	164	23.0%	0.54 [0.47, 2.03]	-			
Total overta	24	104	20	104	23.0%	0.34 [0.10, 1.01]	-			
Total events	24	40.00	39 36-37		0.0.17 - 7	70/				
Heterogeneity: I au-=	0.91; Chi+	= 13.08	s,ατ= 3 (⊢	² = 0.0	04); i* = 7	/%				
Test for overall effect:	Z=1.11 (P	= 0.27)							
Total (95% CI)		631		626	100.0%	0.46 [0.31, 0.70]	◆			
Total events	93		187							
Heterogeneity: Tau ² =	0.45; Chi ² :	= 54.08	6, df = 17 ((P < 0.)	00001); l²	²= 69%				
Test for overall effect: Z = 3.70 (P = 0.0002) Test for subgroup differences: ChiE = 4.75 df = 3 (P = 0.19) IE = 36.9% experimental control]										
. correr cabaroab am	2.011000. VI	4.	0	0.		/v				
IGURE 10										
orest plot of adverse r	eactions.									

of TGP in combination with different conventional therapeutic agents for the treatment of SLE by SLEDAI and these aforementioned indicators provide an evidence-based basis for the future use of TGP in the clinical management of SLE.

Twenty three RCTs involving 1,573 patients were included in this study. The results of the meta-analysis showed that TGP combined with GC and CTX could improve the SLEDAI score, C3, C4, IgA, IgG, IgM, ESR, CRP, 24 h urinary protein, recurrence rate, incidence of adverse reactions, and reduce the average daily dosage of GC and cumulative dosage of CTX. TGP combined with GC and HCQ has more advantages in improving the SLEDAI score, C3, C4, ESR, and 24 h urine protein. TGP combined with GC and TAC improved the SLEDAI score, IgA, IgG, IgM, recurrence rate, and reduced the average daily dosage of GC. TGP combined with GC was more advantageous in improving the SLEDAI score, C3, C4, IgA, IgG, ESR, CRP, 24 h urine protein, recurrence rate, and reduced the average daily dosage of GC. TGP combined with



GC and HCQ or GC and TAC or GC had no significant advantage in terms of the incidence of adverse effects compared with the control group. It shows that TGP combined with different conventional therapeutic agents can effectively and safely reduce SLE disease activity. The certainty of the evidence ranges from low to moderate.

This study strictly follows the PRISMA and GRADE methodology and reports a systematic review of the evidence on the efficacy and safety of TGP in combination with different conventional therapeutic agents for the treatment of SLE. However, our review still has certain limitations: 1) many of the included studies did not describe the implementation process of the randomization protocol, and none of them stated whether the allocationconcealed dosing method was used or whether it was blinded, 2) the efficiency, adverse reaction, and recurrence rate were used as outcome observation indicators, but the evaluation

TABLE 2 GRADE Summary of outcomes of TGP combined with different Western medicines for SLE.

Outcome	Anticipated a (95% CI)	absolute effect	Relative effect (95% CI)	No. of participants (studies)	Certainty of evidence (GRADE)
	Risk with C	Risk difference with T			
SLEDAI	mean (2.88–6.84)	SMD 1.6 (1.99 and 1.22)	-	1,185 (18 RCTs)	$\oplus \oplus \oplus O^1 < Moderate$
SLEDAI (GC + CTX + TGP)	mean (2.88–6.37)	SMD 1.98 (2.5 and 1.46)	-	712 (12 RCTs)	$\oplus \oplus OO^{1, 2} < Low$
SLEDAI (GC + HCQ + TGP)	mean (6.08–6.08)	SMD 0.65 (1.04 and 0.26)	-	106 (1 RCT)	$\oplus \oplus \oplus O^1 < Moderate$
SLEDAI (TGP + GC + TAC)	mean (6.16–6.17)	SMD 0.94 (1.53 and 0.34)	-	154 (2 RCTs)	$\oplus \oplus OO^{1, 2} < Low$
SLEDAI (TGP + GC)	mean (4.71–6.84)	SMD 0.69 (1.08 and 0.29)	-	107 (2 RCTs)	$\oplus \oplus \oplus O^1 < Moderate$
Incidence of adverse reactions	30 per 100	14 per 100 (9 and 21)	RR = 0.46 (0.31 and 0.70)	1,257 (18 RCTs)	$\oplus \oplus OO^{1, 2} < Low$
Incidence of adverse reactions (TGP + GC + CTX)	41 per 100	13 per 100 (9 and 18)	RR 0.31 (0.22, 0.43)	549 (9 RCTs)	$\oplus \oplus OO^{1, 2} < Low$
Incidence of adverse reactions (TGP + GC + HCQ)	6 per 100	4 per 100 (1 and 15)	RR 0.60 (0.15, and 2.44)	166 (2 RCTs)	$\oplus \oplus \oplus O^1 < Moderate$
Incidence of adverse reactions (TGP + GC + TAC)	11 per 100	16 per 100 (5 and 45)	RR 1.40 (0.48, 4.08)	90 (1 RCT)	$\oplus \oplus \oplus O^1 < Moderate$
Incidence of adverse reactions (TGP + GC)	26 per 100	4 per 100 (2 and 12)	RR 0.17 (0.06 and 0.48)	180 (2 RCTs)	$\oplus \oplus OO^{1, 2} < Low$
Recurrence rate	31 per 100	9 per 100 (6 and 13)	RR 0.28 (0.19, and 0.41)	359 (10 RCTs)	$\oplus \oplus \oplus O^1 < Moderate$

¹There is a risk of bias in the implementation of random methods.

 $^2\mathrm{I}^2{\geq}50\%$ with large heterogeneity.

criteria were inconsistent, 3) the baseline information of included patients, e.g., age range, cause of disease, extent of SLEDAI, and the duration of treatment had large deviations, 4) the sample size of individual studies was small, 5) potential causal relationships between adverse reactions and TGP were not assessed. In conclusion, the quality of the included studies is relatively low. Therefore, larger and more rigorous RCTs focusing on TGP for the treatment of SLE are needed to verify.

future studies, following For we make the recommendations. First, clinical studies should use enhanced methodological quality, such as proper application of randomization, allocation concealment, and blinding. Second, the design of clinical study protocols is equally important. Investigators should refer to the latest guidelines for controlled trials of SLE treatment. Third, the selection of outcome indicators in clinical studies should clearly specify the criteria for the evaluation of efficacy and adverse effects. Overall, future studies should focus on adopting standardized clinical study designs as a way to improve the methodological and reporting quality of systematic evaluation or meta-analysis, so as to make the conclusion more clinically applicable and provide reliable evidence for clinicians.

5 Conclusion

According to the current limited evidence, TGP as an adjuvant therapy, combined with conventional therapeutic agents, may effectively and safely reduce disease activity in SLE patients. Therefore, TGP may become a promising complementary therapy whose long-term efficacy should be explored in the future. However, due to the low quality of both the methods and evidence, we should be cautious about the conclusion drawn from the included studies.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

References

Author contributions

GXH, LSW, and LH designed the study, GXH and LCQ searched and screened the literature, WSW and CYM extracted data from the included literature, LH resolved differences, GXH and WSW assessed the bias of risk, LSW and GHT assessed the certainly of evidence, the article was written by GXH, LSW, and LH revised the paper.

Funding

This study was funded by the National Natural Science Foundation of China (No. 81874465, 81573952), Henan Province Traditional Chinese Medicine Special Research Project (No. 20-21ZYZD16 and 20-21JDZY010), and Research and Innovation Project of Henan University of Chinese Medicine (No.2021KYCX003), Henan Province Science and Technology Research Project (No.222102310392), Henan Provincial Science and Technology Program Joint Fund Project (No. 222301420089).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar. 2022.932874/full#supplementary-material

Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., et al. (2019). 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann. Rheum. Dis.* 78 (9), 1151–1159. doi:10.1136/annrheumdis-2018-214819

Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et al. (2011). GRADE guidelines: 3. Rating the quality of evidence. *J. Clin. Epidemiol.* 64 (4), 401–406. doi:10.1016/j.jclinepi.2010.07.015

Bultink, I. E. M., de Vries, F., van Vollenhoven, R. F., and Lalmohamed, A. (2021). Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. *Rheumatol. Oxf.* 60 (1), 207–216. doi:10. 1093/rheumatology/keaa267

Cai, H. Y., Cai, Z. H., and Shao, L. P. (2017). Therapeutic effect of total glucosides of paeony on systemic lupus erythematosus. *J. Chin. Physician* 19 (3), 445–447. doi:10.3760/cma.j.issn.1008-1372.2017.03.036

Chen, H. L., Shen, L. J., Hsu, P. N., Shen, C. Y., Hall, S. A., and Hsiao, F. Y. (2018). Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: Findings from a 12-year longitudinal study. J. Rheumatol. 45 (1), 83–89. doi:10.3899/jrheum.160214

Chen, J. (2013). Therapeutic effects and adverse effects of total glucosides of glycoside on systemic lupus erythematosus. *China Med. Front.* 8 (06), 28+27.

Chen, Y., Wang, L., Cao, Y., and Li, N. (2022). Total glucosides of paeonia lactiflora for safely reducing disease activity in systemic lupus erythematosus: A systematic review and meta-analysis. *Front. Pharmacol.* 13, 834947. doi:10.3389/fphar.2022.834947

Chinese Rheumatology Association (2020). 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. *Chin. J. Intern. Med.* 03, 172–185. doi:10.3760/cma.j.issn.0578-1426.2020.03.002

Dima, A., Opris, D., Jurcut, C., and Baicus, C. (2016). Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? *Lupus* 25 (11), 1173–1179. doi:10.1177/0961203316651742

Durcan, L., O'Dwyer, T., and Petri, M. (2019). Management strategies and future directions for systemic lupus erythematosus in adults. *Lancet* 393 (10188), 2332–2343. doi:10.1016/s0140-6736(19)30237-5

Durcan, L., and Petri, M. (2020). The clinical and serological associations of hypocomplementemia in a longitudinal sle cohort. *Semin. Arthritis Rheum.* 50 (5), 1081–1086. doi:10.1016/j.semarthrit.2020.06.009

Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J., et al. (2019). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann. Rheum. Dis.* 78 (6), 736–745. doi:10.1136/ annrheumdis-2019-215089

Fava, A., and Petri, M. (2019). Systemic lupus erythematosus: Diagnosis and clinical management. *J. Autoimmun.* 96, 1–13. doi:10.1016/j.jaut.2018. 11.001

Feng, P. Z., Ji, L. H., and Yu, L. L. (2017). Clinical effect study of cyclophosphamide combined with total glucosides of paeony in the treatment of systemic lupus erythematosus. *Laboratory Med Clin* 14 (2), 113–114. doi:10.3969/j. issn.1672-9455.2017.26.049

Feng, Z., Zhang, B. Q., Zhu, Y. M., Yu, B. B., Fu, L., Zhou, L. L., et al. (2019). The effectiveness and safety of total glucosides of paeony in primary Sjogren's syndrome: A systematic review and meta-analysis. *Front. Pharmacol.* 10, 550. doi:10.3389/fphar.2019.00550

Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., Schünemann, H. J., et al. (2008). What is "quality of evidence" and why is it important to clinicians? *Bmj* 336 (7651), 995–998. doi:10.1136/bmj.39490.551019.BE

He, D. Y., and Dai, S. M. (2011). Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall., a traditional Chinese herbal medicine. *Front. Pharmacol.* 2, 10. doi:10.3389/fphar.2011.00010

Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 40 (9), 1725. doi:10.1002/art.1780400928

Huang, S. P., Snedecor, S. J., Nanji, S., Lloyd, E., and Bell, C. F. (2022). Real-world effectiveness of belimumab in systemic lupus erythematosus: A systematic literature review. *Rheumatol. Ther.* 9 (4), 975–991. doi:10.1007/s40744-022-00454-9

Huang, Y., Wang, H., Chen, Z., Wang, Y., Qin, K., Huang, Y., et al. (2019a). Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: A meta-analysis. *Drug Des. devel. Ther.* 13, 1969–1984. doi:10.2147/dddt.S207226

Huang, Y., Wang, H., Chen, Z., Wang, Y., Qin, K., Huang, Y., et al. (2019b). Synergistic and hepatoprotective effect of total glucosides of paeony on ankylosing spondylitis: A systematic review and meta-analysis. *Front. Pharmacol.* 10, 231. doi:10.3389/fphar.2019.00231

Iaccarino, L., Bartoloni, E., Carli, L., Ceccarelli, F., Conti, F., De Vita, S., et al. (2015). Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian multicentre registry. *Clin. Exp. Rheumatol.* 33 (4), 449–456.

Jiang, H., Li, J., Wang, L., Wang, S., Nie, X., Chen, Y., et al. (2020). Total glucosides of paeony: A review of its phytochemistry, role in autoimmune diseases, and mechanisms of action. *J. Ethnopharmacol.* 258, 112913. doi:10.1016/j.jep.2020. 112913

Jorge, A. M., Lu, N., Zhang, Y., Rai, S. K., and Choi, H. K. (2018). Unchanging premature mortality trends in systemic lupus erythematosus: A general populationbased study (1999-2014). *Rheumatol. Oxf.* 57 (2), 337–344. doi:10.1093/ rheumatology/kex412

Kao, J. H., Lai, T. T., Lu, C. H., Lan, T. Y., Hsieh, Y. T., Shen, C. Y., et al. (2022). Characteristics and potential risk factors of hydroxychloroquine retinopathy in patients with systemic lupus erythematosus: Focusing on asian population. *J. Ocul. Pharmacol. Ther.* doi:10.1089/jop.2022.0060 Knight, J. H., Howards, P. P., Spencer, J. B., Tsagaris, K. C., and Lim, S. S. (2016). Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: An analysis using the GOAL study. *Lupus Sci. Med.* 3 (1), e000139. doi:10.1136/lupus-2015-000139

Kwon, H. H., Bang, S. Y., Won, S., Park, Y., Yi, J. H., Joo, Y. B., et al. (2018). Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus. *Lupus* 27 (10), 1644–1651. doi:10.1177/0961203318784648

Li, M., Li, J., Wang, J., Li, Y., and Yang, P. (2018a). Serum level of anti- α -enolase antibody in untreated systemic lupus erythematosus patients correlates with 24-hour urine protein and D-dimer. *Lupus* 27 (1), 139–142. doi:10.1177/0961203317721752

Li, M., Zhang, W., Leng, X., Li, Z., Ye, Z., Li, C., et al. (2013). Chinese SLE treatment and research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. *Lupus* 22 (11), 1192–1199. doi:10.1177/0961203313499086

Li, X. Q., and Zheng, L. Y. (2020). Clinical efficacy of cyclophosphamide combined with total glucosides of paeony in the treatment of systemic lupus erythematosus. *Pract. Clin. Appl. Integr. Tradit. Chin.* 20 (15), 123–124. doi:10. 13638/j.issn.1671-4040.2020.15.063

Li, Y. M. (2013). Clinical effects of Total Glycosides of Paeony in the adjuvant treatment of systemic lupus erythematosus. *J. Clin. Ration. Drug Use* 6 (22), 68–69. doi:10.3969/j.issn.1674-3296.2013.22.054

Li, Z., Yang, H. J., and Xie, Q. (2018b). Clinical study of total glucosides of paeony capsule combined with Tacrolimus in the treatment of systemic lupus erythematosus. *Drugs & Clin.* 33 (6), 1513–1517. doi:10.7501/j.issn.1674-5515.2018.06.050

Lin, G. Y., and Liu, C. X. (2016). Observation of the therapeutic effects and adverse effects of Total Glycosides of Paeony on systemic lupus erythematosus. *North Pharm.* 13 (2), 155.

Liu, W., Cai, M., Wang, X., and Zhou, F. (2016). Magnetite-loaded thermosensitive nanogels for bioinspired lubrication and multimodal friction control. ACS Macro Lett. 5 (4), 144–148. doi:10.1021/acsmacrolett.5b00860

Luo, J., Jin, D. E., Yang, G. Y., Zhang, Y. Z., Wang, J. M., Kong, W. P., et al. (2017). Total glucosides of paeony for rheumatoid arthritis: A systematic review of randomized controlled trials. *Complement. Ther. Med.* 34, 46–56. doi:10.1016/j. ctim.2017.07.010

Martins, N. F. E., Seixas, M. I., Pereira, J. P., Costa, M. M., and Fonseca, J. E. (2017). Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. *Clin. Rheumatol.* 36 (12), 2853–2854. doi:10.1007/s10067-017-3797-0

Mu, L., Hao, Y., Fan, Y., Huang, H., Yang, X., Xie, A., et al. (2018). Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. *Lupus* 27 (10), 1742–1752. doi:10.1177/0961203318789788

Olfat, M., Silverman, E. D., and Levy, D. M. (2015). Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. *Lupus* 24 (9), 966–972. doi:10.1177/0961203315578764

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Bmj* 372, n71. doi:10.1136/bmj.n71

Peng, H. (2018). Clinical effect of cyclophosphamide combined with total glucosides of paeony in the treatment of systemic lupus erythematosus. *Med. Front.* 8 (15), 148–149. doi:10.3969/j.issn.2095-1752.2018.15.120

Petri, M., Orbai, A. M., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., et al. (2012). Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 64 (8), 2677–2686. doi:10.1002/art.34473

Rees, F., Doherty, M., Grainge, M. J., Lanyon, P., and Zhang, W. (2017). The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. *Rheumatol. Oxf.* 56 (11), 1945–1961. doi:10.1093/rheumatology/kex260

Steiger, S., Ehreiser, L., Anders, J., and Anders, H. J. (2022). Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. *Front. Immunol.* 13, 999704. doi:10.3389/fimmu.2022.999704

Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., et al. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. *Bmj* 366, 14898. doi:10.1136/bmj.14898

Sun, X. W. (2013). Evaluation of total glucosides of paeony combined with lowdose hormone in the treatment of 96 cases of systemic lupus erythematosus. *J. Pract. Clin. Med.* 17 (13), 124–125. doi:10.7619/jcmp.201313045

Tamirou, F., Husson, S. N., Gruson, D., Debiève, F., Lauwerys, B. R., and Houssiau, F. A. (2017). Brief report: The euro-lupus low-dose intravenous

cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-müllerian hormone. *Arthritis Rheumatol.* 69 (6), 1267–1271. doi:10.1002/art.40079

Wang, D., and Wang, S. S. (2015). Therapeutic effect of total glucosides of paeony on systemic lupus erythematosus and its effect on CD11a expression. *China J. Lepr. Skin. Dis.* 11, 659–661.

Wang, Y., Han, M., Pedigo, C. E., Xie, Z. M., Wang, W. J., and Liu, J. P. (2021). Chinese herbal medicine for systemic lupus erythematosus: A systematic review and meta-analysis of randomized, placebo-controlled trials. *Chin. J. Integr. Med.* 27 (10), 778–787. doi:10.1007/s11655-021-3497-0

Wang, Z. J., Wang, J., and Li, P. L. (2013). Clinical effect analysis of total glucosides of paeony in the treatment of systemic lupus erythematosus. *Zhejiang Clin. Med.* 15 (3), 369–371.

Wu, Q., Yu, H. H., Luo, R., He, J. T., Luo, S. W., and Yu, Q. (2022). Total glucosides of paeony improve renal injury in mice with systemic lupus erythematosus by regulating TLR9/MyD88/NF-KB pathway. *Chin. J. Exp. Tradit. Med. Formulae* 28 (12), 103–110. doi:10.13422/j.cnki.syfjx.20221239

Wu, X., Shi, S., Chen, Q. Y., and Jiao, L. J. (2020). Effects of total glucosides of paeony combined with cytoxan in the treatment of systemic lupus erythematosus in CD4+CD25+ T cell in peripheral blood. [Effects of total glucosides of paeony combined with cytoxan in the treatment of systemic lupus erythematosus in CD4+CD25+T cell in peripheral blood]. *Chin. J. Dermatovenereol. Integr. Tradit. West. Med.* 19 (1), 52–56.

Xiang, S. (2020). Cyclophosphamide combined with total glucosides of paeony in the treatment of systemic lupus erythematosus. *China Health Care Nutr.* 30 (25), 282.

Xu, F. (2015). Clinical effect of cyclophosphamide combined with total glucosides of paeony in the treatment of systemic lupus erythematosus. *Shaanxi Med. J.* 44 (8), 1081–1082. doi:10.3969/j.issn.1000-7377.2015.08.075

Xu, Y. (2020). Clinical efficacy and safety of cyclophosphamide combined with total glucosides of paeony in the treatment of systemic lupus erythematosus. *China Med. Guide* 18 (10), 83–84. doi:10.15912/j.cnki.gocm.2020.10.036

Xue, Y., and Lyu, Y. X. (2019). Clinical observation of total glucosides of paeony capsule in the treatment of mild systemic lupus erythematosus. *Guangming J. Chin. Med.* 34 (13), 2022–2023. doi:10.3969/j.issn.1003-8914. 2019.13.032

Yang, M. J. (2016). Study of the efficacy of cyclophosphamide in combination with total glycosides of paeony in the treatment of patients with systemic lupus erythematosus. *Psychologist* 22 (24), 41–42.

Yang, S. J., Feng, A. J., Sun, Y., Zhang, L., Bo, F. M., and Li, L. J. (2021). Research progress on mechanism and pharmacological activities of total glucosides of paeony. *Chin. J. Mod. Appl. Pharm.* 38 (13), 1627–1633. doi:10.13748/j.cnki. issn1007-7693.2021.13.015

Yang, X., and Li, H. P. (2019). Clinical efficacy and immune function of total glucosides of paeony in patients with systemic lupus erythematosus. *World Chin. Med.* 14 (5), 1270–1273. doi:10.3969/j.issn.1673-7202.2019.05.045

Yu, H. Y., Peng, J. H., and Ye, X. Y. (2019). Clinical efficacy and side effects of cyclophosphamide combined with total glucosides of paeony on systemic lupus erythematosus. *Shanghai Med. Pharm.* 40 (9), 35–37. doi:10.3969/j.issn.1006-1533. 2019.09.012

Zhang, L., and Wei, W. (2020). Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. *Pharmacol. Ther.* 207, 107452. doi:10.1016/j.pharmthera.2019.107452

Zhang, Y. (2020). Evaluation of total glucosides of paeony capsule combined with Tacrolimus in the treatment of systemic lupus erythematosus. *Contemp. Med. Forum* 18 (6), 146–147. doi:10.3969/j.issn.2095-7629.2020.06.115

Zhao, L., Huang, J. M., and Xuan, X. (2020). Clinical observation of total glucosides of paeony in adjuvant treatment of systemic lupus erythematosus. *J. Pract. Tradit. Chin. Intern. Med.* 34 (8), 89–91. doi:10.13729/j.issn.1671-7813. Z20200543

Zhu, Y. H., and Wei, C. H. (2009). Clinical observation of total glucosides of paeony combined with low-dose hormone in the treatment of 35 cases of systemic lupus erythematosus. *Shandong Med. J.* 49 (5), 100–101. doi:10.3969/j.issn.1002-266X.2009.05.055